

# SESSIONS

MAR 16 - 16/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## BiotechBikers Networking Ride

10:00 - 14:00

Join BiotechBikers for a cycle into the foothills of the Alps. We will meet mid-morning outside of the city (a train ride will be necessary) and rides of two lengths will be offered: ~35km and ~60km. You must be comfortable riding in a group, on a road bike, and with hill climbing.

High-end bike rentals are available, with pedals of your choice. Helmets are mandatory and can be provided as well.

Meeting point: Erba Rail Station, 22306 Erba, Province of Como, Italy

Meeting time: 10:30 am, at the latest!

Duration of ride: short ride, 2.5 hours approx.; long ride, 4.5 hours approx. Should be back in city centre by 4pm.

[SIGN UP HERE](#)

## Pre-event registration and badge pick-up (14:00 - 19:00 CET )

14:00 - 14:30

**Time:** 14:00 – 19:00 CET

**Location:**

Allianz MiCo

Central Building

Entrance via Gate 5

Corner of Viale Teodorico & Viale Lodovico Scarampo  
20149 Milano MI, Italy

## Newcomer Program and Reception

17:00 - 18:30

**Date:** Sunday, March 16 2025

**Time:** 17:00 - 18:30 CET

**Location:** BIO-Europe Spring Conference Venue, Allianz MiCo, Coral 1

Maximize your experience: The Newcomer's Program provides first-time BIO-Europe Spring participants and seasoned attendees alike the opportunity to maximize their experience at the event through a short introduction to what you can expect over the three days, some tried and tested best practice instruction, and a chance to stretch your networking muscles meeting other newcomers.

Registration is for registered attendees only, and is available through partneringONE.

## BIO-Europe Spring Welcome Reception

19:00 - 21:00

**Date:** Sunday, March 16 2025

**Time:** 19:00 – 21:00 CET

**Location:**

Principe di Savoia Hotel

Piazza della Repubblica, 17, 20124 Milan, Italy

### Only badge pickup is available

Principe di Savoia is a luxurious five-star hotel, renowned for its elegant design, world-class hospitality, and prime location near the city's cultural and fashion districts. Kick off BIO-Europe Spring 2025 in style! Enjoy an evening of networking, fine drinks, and conversation in a sophisticated and elegant setting.

# SCHEDULE

MAR 16 - 16/03/2025

BIO-Europe Spring  
THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	
10:00	10:00 - BiotechBikers Networking Ride
14:00	14:00 - Pre-event registration and badge pick-up (14:00 - 19:00 CET )
17:00	17:00 - Newcomer Program and Reception
19:00	19:00 - BIO-Europe Spring Welcome Reception

# SESSIONS

DAY 1 - 17/03/2025

## Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)

07:45 - 08:00

Location:

### Allianz MiCo

Central Building  
Entrance via Gate 5  
Corner of Viale Teodorico & Viale Lodovico Scarampo  
20149 Milano MI, Italy

Light Breakfast: **served until 10:45**

## Partnering: one-to-one meetings (9:00 - 18:30 CET)

08:00 - 08:30

One-to-one meetings at BIO-Europe Spring will be scheduled during the hours below:

Meetings on this day will start at **9:00 - 18:30 CET**.

## Buzz Session: Winning presentations, influencing partnerships

08:30 - 10:00  
Relax and Learn.

### Location: Coral 1

This session is an interactive workshop which aims to provide participants with practical tools, ideas and best practices to consider when creating and structuring your pitch presentations. It also dives into understanding how to enhance your professional behaviour and tap into your emotional intelligence when in pitching, partnering and negotiating situations, to lead to successful long-term partnerships.

### Part 1 – Your presentation sets a precedent for partnership

- Influence or educate?
- Utilising Aristotle's four rhetorical appeals
- Tuning in to others' pains and gains

### Part 2 - What's your point?

- Preparing your most compelling message
- Less is more
- What do you want them to take away?

### Part 3 – Packaging a winning presentation

- Opening for attention
- A powerful structure to reinforce your key messages
- Closing for impact

### Participants

**Moderator: Simon Fagg** - Founder, With Leadership

## partneringONE essentials workshop

09:30 - 10:00  
Relax and Learn

### Location: Exhibit Hall Stage

This interactive workshop is for delegates new to partnering. What can you expect from partnering, and what do others expect from you? Principles around timing, human nature, and partnering etiquette will be applied to the partneringONE process. This session will give you a clear understanding of tactics to generate the best ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have. This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can't attend a session, drop by the partnering help desk with any questions.

### Participants

**Speaker: Jordan Stillman** - Project Manager, partneringOne

## Opening remarks

10:00 - 10:30  
Business of Biotech

### Location: Coral 3

### Participants

**Panelist: Claire Macht** - Portfolio Director, Europe, EBD Group

**Panelist: Fiorenza Lipparini** - Director General, Milano&Partners

**Panelist: Chad Wessel** - Director, Industry Analysis, Biotechnology Innovation Organization (BIO)

## Italian roots, global reach: Biotech investment insights - a dynamic conversation with Graziano Seghezzi and Francesco De Rubertis

10:30 - 11:15  
Business of Biotech

### Location: Coral 3

Join globally recognized venture capitalists Graziano Seghezzi of Sofinnova Partners and Francesco De Rubertis of Medicxi, for a dynamic and insightful fireside chat. Despite their distinct approaches to biotech investment, both share a deep passion for shaping the future of the industry. During the session, they will delve into their successes, failures, and key lessons from decades of experience, whilst providing an overview of the evolving biotech investment landscape. Attendees will gain practical tips, actionable insights, and strategies to capture the attention of top investors- valuable guidance for those navigating the biotech innovation ecosystem.

### Participants

**Moderator: Mike Ward** - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

**Panelist: Francesco De Rubertis** - Co-Founder and Partner, Medicxi

**Panelist: Graziano Seghezzi** - Managing Partner, Sofinnova Partners

## Deals in vogue: Navigating M&A and business development in a shifting global landscape

11:30 - 12:15  
Business of Biotech

### Location: Coral 3

As the biotech and pharma industries grapple with a dynamic global environment, deal-making remains a vital lever for growth and innovation. This session will address strategies for navigating the current financing environment, geopolitical tensions, and the opportunities expected to drive increased deal-making activity in 2025. Discover how collaboration and investment can propel the industry forward in the face of evolving challenges.

### Participants

**Moderator: Martina Molsbergen** - CEO, C14 Consulting Group, LLC

**Panelist: Fabrizio Conicella** - VP - Center of Open Innovation & Competence, Chiesi Group

**Panelist: Nick Gagnon** - VP, Head of Oncology Global Partnering, IPSEN

**Panelist: Konstantina Katcheves** - SVP, Global Business Development and Acquisitions, Teva Pharmaceuticals

**Panelist: Matthias Muellenbeck** - SVP, Head Global Business Development & Alliance Management, Merck Healthcare KGaA

# SESSIONS

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Lunch

12:00 - 13:00  
Lunch

## partneringONE power up workshop

12:00 - 12:30  
Relax and Learn

### Location: Coral 1

Pick up your lunch and join us for this interactive workshop for delegates familiar with partnering who want to up their game. We will cover best practices for collaborating with colleagues, saving time, increasing response rates and acceptance rates, and partneringONE power features to support optimal partnering etiquette. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events. There will be plenty of opportunities to ask our partneringONE expert any questions you may have. This session is limited to 40 people. Please reserve your seat by adding the session to your personal agenda. If you can't attend a session, drop by the partnering help desk with any questions.

### Participants

**Speaker: Jordan Stillman** - Project Manager, partneringOne

## Seamless advancements: Paving the future of cell and gene therapy

13:00 - 13:45  
Therapeutic Insights

### Location: Coral 2

Explore the future of cell and gene therapy as industry experts tackle pressing questions and map the next wave of innovation. Discover the latest progress in the field whilst examining the current shortcomings and understanding the advancements still required to unlock the full potential of the therapeutic area.

### Participants

**Moderator: Paola Pozzi** - Partner, Sofinnova Partners

**Panelist: Karen Aiach-Pignet** - CEO, Genespire

**Panelist: Natalia Misciattelli** - CEO, AAVantgarde Bio

**Panelist: Francesca Pasinelli** - Managing Director, Fondazione Telethon

## Cell & Gene Therapies: Accelerated Biosciences Corp.

13:00 - 13:15  
Company Presentations: Coral 1

### Location: Coral 1

Accelerated Biosciences is a regenerative medicine company with freedom-to-operate for the human Trophoblast Stem Cell (hTSC) platform, the earliest stem cells that can be sourced without ethical issues with over 117 granted and pending patents. We are providing GMP cells with a complete regulatory package to help cell and gene therapy developers accelerate their product time to market by 3 to 5 years with a potential of millions in savings. We have effectively de-risked the starting cell source decision for the regenerative medicine industry. We are available for partnering and licensing opportunities.

### Participants

**Presenter: Yuta Lee** - CEO, Accelerated Biosciences Corp.

## CNS/Neurology: Neurochlore

13:00 - 13:15  
Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

we use NKCC1 inhibitors to treat autism but also Brain tumors:  
Autism: The co-transporter NKCC1 that controls brain inhibition is overactive in autism, and many other disorders. The NKCC1 inhibitor Bumetanide (BUM) attenuates autism severity in 9 independent phase 2 trials (1030 children Xiao et al 2024). Following the unexpected failure of phase 3 trial, we have identified up to 30-40% of BUM responder children using Machine Learning reanalysis of phase 3. this implies that a phase 3 centered on these identified children's subpopulations will be successful.  
Brain Tumors and Glioblastoma: (BUM) and the Microtubule acting drug Mebendazole (MEB) exert potent anticancer activity. NKCC1 activity is enhanced in Glioblastoma (GBM) & lung, pancreas, kidney, & prostate cancers and its hyper- activity correlates with GBM severity gradient. Treating GBM patients with Meb and Temozolomide demonstrated a 21-month survival time at 2 years & acceptable toxicity (Gallia et al 2021). We show that MEB & BUM exert complementary, and synergistic actions in GBM and meningioma tumoroids surgically extracted from patients. The patent protected combo increased survival of a patient with large brain stem tumor. Our offer is dual:  
i) short term autism: performing a phase 2/3 with inclusion criteria restricted to children having the criteria identified by ML to lead rapidly to a treatment in the market covering the entire pediatric population (2-18 years old)  
ii) short term Tumors: performing a phase 2/3 using the combo to treat Brain tumors notably Glioblastoma and meningioma.  
ii) long term - conduct our best proprietary newly synthesizedc NKCC1 inhibitors to IND-enabling studies and phase1 to treat autism brain tumors but also many disorders sensitive to NKCC1 inhibition (brain trauma, infantile epilepsies and temporal lobe epilepsies, CVI, chronic pain, Parkinson disease).

### Participants

**Presenter: Yehzekel ben-ari** - CEO, Neurochlore

# SESSIONS

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Cell & Gene Therapies: AAVnerGene Inc.

13:15 - 13:30

Company Presentations: Coral 1

### Location: Coral 1

AAVnerGene Inc. is an innovative biotech company developing new technologies to make AAV based gene therapy more accessible and affordable. It was founded in 2019 at Rockville, MD USA.

AAVnerGene addresses two major bottleneck problems: Manufacture and Delivery efficiency. The gene therapy drugs usually need very high dose, which leads to high side effects and high cost, seriously hindering research and drug development of AAV gene therapy. AAVnerGene developed AAVone to solve the manufacture problem, and ATHENA to solve the low delivery efficiency problem.

AAVone is a new one-plasmid AAV production system that has much higher production efficiency, ease to process and scale up, high quality, much lower cost and other advantages over the widely used triple plasmid transfection system. Application of AAVone for AAV production will solve the AAV manufacture problem, and make AAV gene therapy development easier, faster, effective and less costly.

AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening platform has high complexity to find the best AAV for each specific disease therapy, so to increase productivity, efficiency and specificity while decrease manufacture pressure, side effects, immunity and price. With tons of in house produced reliable data, we train our proprietary AI model to screen, analyze and rational-design efficient AAVs for next generation AAV gene therapy. We have engineered different AAVs for brain, lung, eye, heart, kidney and liver, and these AAVs can increase the delivery efficiency by hundreds of times. These technologies are open to collaborate, licensing or sell.

Please refer to [www.AAVnerGene.com](http://www.AAVnerGene.com) for more information and send your questions to [Daozhan.yu@aavnergene.com](mailto:Daozhan.yu@aavnergene.com).

### Participants

**Presenter:** Daozhan Yu - CEO, AAVnerGene Inc.

## CNS/Neurology: Vesper Bio

13:15 - 13:30

Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

Vesper Bio is a private, VC-backed, clinical stage company with world-leading domain expertise in Vps10p domain receptors, developing a rich pipeline of first-in-class small molecule sortilin modulators for a number of critical unmet medical needs in the CNS space.

### Participants

**Presenter:** Lovisa Sunesson - Director of Business Development, Vesper Bio

## Cell & Gene Therapies: Kolon Life Science

13:30 - 13:45

Company Presentations: Coral 1

### Location: Coral 1

Kolon Life Science (listed on KOSDAQ), a subsidiary of Kolon Group, is a South Korean biotech company established in 2000. One of its main business areas includes novel biopharmaceuticals, specializing in cell and gene therapies.

There are three gene therapy drug candidates: TG-C for osteoarthritis(US Ph 3 ongoing), KLS-2031 for neuropathic pain (US Ph 1/2a completed), and KLS-3021 as oncolytic virus.

We are currently seeking partners for business development, collaborative research and co-development of our drug assets.

### Participants

**Presenter:** Jung Jong Cho - Head of Bio Business Division, Kolon Life Science

## CNS/Neurology: Owl Therapeutics

13:30 - 13:45

Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

**Mission:** To develop and market novel neurotherapeutics for traumatic brain injury (TBI) and associated conditions like post-traumatic epilepsy (PTE) and Alzheimer's disease (AD).

**Vision:** To pioneer artificial intelligence (AI)- and diagnostic-powered brain health pipelines to improve the lives of patients.

Owl is the first clinical-stage, AI- and diagnostic-powered biopharmaceutical company focused on advancing neurotherapeutics for TBI and associated conditions. The company is set to embark on Phase 2 trials for its lead asset OWL-1410.

### Participants

**Presenter:** William Haskins - Co-Founder and CEO, Owl Therapeutics

## Cell & Gene Therapies: Basecamp Research

13:45 - 14:00

Company Presentations: Coral 1

### Location: Coral 1

Basecamp Research is a biotech company that is bridging the data gap to make better predictions for protein and genome design using AI. Basecamp has built and legally owns a database of diverse sequences 900X larger than public databases combined that represent the Earth's diverse biomes to learn how nature creates biological molecules. We employ this platform to solve difficult biological problems not accessible to scientists without the use of large data and compute power. Basecamp is now using its proprietary database to solve programmable gene insertion, the next generation of gene writing tools for cell and gene therapies.

### Participants

**Presenter:** Glen Gowers - CEO, Basecamp Research

## CNS/Neurology: Lario Therapeutics Ltd.

13:45 - 14:00

Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

Lario Therapeutics Limited ("Lario") is a preclinical-stage drug discovery company based in Edinburgh (UK). Lario has been incubated and co-founded by Epidarex-Exeed and Axxam SpA and is developing first-in-class precision medicines for epileptic and neurological disorders. Lario Therapeutics are developing first-in-class precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson's disease.

### Participants

**Presenter:** Henning Steinhagen - CEO, Lario Therapeutics Ltd.

# SESSIONS

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Deconstructing breakthroughs: Unpacking lessons from Alys Pharmaceuticals on advancing Immuno-Dermatology

14:00 - 14:45

Business of Biotech

**Location:** Coral 2

The launch of Alys Pharmaceuticals with \$100 million in financing by Medicxi marks a transformative milestone in the biotech landscape. Formed from the merger of six asset-centric companies, Alys represents a bold, R&D-driven approach to tackling significant unmet needs in immuno-dermatology. With a pipeline spanning cutting-edge modalities—from peptides to vectorized siRNA—Alys is set to deliver groundbreaking treatments for prevalent conditions like chronic urticaria, atopic dermatitis, vitiligo, and alopecia areata, as well as rare and underserved dermatological indications.

This fireside chat will explore the strategic vision and innovative framework that powered Alys' formation, shedding light on how startups and biotech companies can leverage similar models to accelerate their growth and impact. Leading KOL, Dr Brian Kim, will join Francesco De Rubertis to highlight the importance of following the science and listening to physicians to determine unmet medical needs. The session will highlight the critical opportunities available for advancing science, securing funding, and building sustainable pipelines. Attendees will gain actionable lessons on how to harness asset-centric strategies, multi-platform pipelines, and cutting-edge science to transform their therapeutic vision into reality.

Whether you're an early-stage innovator or an established biotech seeking inspiration, this discussion will offer invaluable guidance on scaling breakthroughs and driving the next generation of innovation in life sciences.

### Participants

**Moderator:** Mary Clark - CEO, Optimum Strategic Communications

**Panelist:** Francesco De Rubertis - Co-Founder and Partner, Medicxi

**Panelist:** Brian S. Kim - Sol and Clara Kest Professor of Dermatology and Co-Founder, Icahn School of Medicine at Mount Sinai and Alys Pharmaceuticals

## Autoimmune/Inflammation: Canopy Immuno Therapeutics

14:00 - 14:15

Company Presentations: Coral 1

**Location:** Coral 1

Canopy is an emerging biotech redefining autoimmune therapeutics through its groundbreaking Antigen-Drug Conjugate (AgDC) platform. Backed by leading US-based VCs, the company is led by Dr. Kfir Oved, a serial bio-entrepreneur, alongside Chairman Cedric Francois (NASDAQ:APLS) and board member and investor John Cox (NASDAQ:DYNE).

AgDCs utilize two distinct MoAs to precisely target both autoreactive antibodies and pathological B-cell clones, sparing 99.9% of protective immunity. This innovative, non-immunosuppressive approach can potentially deliver long-term remission or even a cure, positioning AgDCs as potential first-line therapy for antibody-mediated autoimmune diseases.

Canopy is on track to initiate a Phase 1 trial for AChR+ MG in H1/26. Backed by robust IP including 14 patents across 8 patent families, the company's pipeline covers Graves' disease/Thyroid Eye Disease (TED), Pemphigus Vulgaris, Membranous Nephropathy, Immune Thrombocytopenic Purpura (ITP), and MuSK MG.

### Participants

**Presenter:** Kfir Oved - CEO, Founder, Canopy Immuno Therapeutics

## CNS/Neurology: Tonix Pharmaceuticals Holding Corp.

14:00 - 14:15

Company Presentations: Exhibit Hall Stage

**Location:** Exhibit Hall Stage

Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix's development portfolio is focused on central nervous system (CNS) disorders.

Tonix's CNS portfolio also includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction.

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases.

Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD's Defense Threat Reduction Agency (DTRA) for up to \$34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments.

Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, MD. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

### Participants

**Presenter:** Seth Lederman - CEO, Tonix Pharmaceuticals Holding Corp.

# SESSIONS

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Autoimmune/Inflammation: Insilico Medicine

14:15 - 14:30

Company Presentations: Coral 1

### Location: Coral 1

As a trailblazer in the AI-DD field, Insilico Medicine continues to innovate in developing AI tools for drug discovery and other science. We are expanding AI offerings in the generative biologics space, investing in robotics and AI combo, deepening our Chemistry42 offerings, and expanding AI efforts in sustainability. On the drug pipeline side, we have 20+ programs covering oncology, fibrosis, immunology and CNS, some of which are at Phase I or Phase II stage. We want to generate clinically meaningful data for the drug candidates that come from our AI-driven discovery programs and do more biopharma partnership deals.

### Participants

**Presenter: Michelle Chen** - CBO, Insilico Medicine

## Cardiovascular: TAHO Pharmaceuticals

14:15 - 14:30

Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

TAHO Pharmaceuticals Ltd., founded in 2010 and headquartered in Taipei, Taiwan, is a publicly listed company on the Taipei Exchange Index. TAHO is committed to revolutionizing drug delivery through innovation. We focus on developing advanced formulations that enhance the administration, safety, and efficacy of existing oral and injectable drug compounds. Guided by our mission to improve patient quality of life, we design and deliver next-generation solutions to meet the unmet needs of diverse populations, particularly those facing challenges with traditional medication forms.

At the core of TAHO's success is our ability to harness advanced proprietary drug delivery technologies. By creating patient-friendly formulations, we aim to enhance compliance, therapeutic efficacy, and overall convenience. Our Transepithelial Delivery System (TDS) platform is a groundbreaking innovation in pharmaceutical delivery, enabling the direct administration of drug compounds into the bloodstream. This proprietary technology operates through two primary modes:

**Transdermal Delivery:** Medication is administered through the skin using patches that provide sustained, controlled release of active ingredients. This approach eliminates the need for injections or frequent oral dosing, making it particularly beneficial for patients with chronic conditions.

**Transmucosal Delivery:** Drugs are absorbed via the oral mucosa through oral thin film technology, offering rapid onset of action. This method ensures enhanced bioavailability and improved patient experience.

TAHO Pharmaceuticals is not merely developing new ways to deliver medication—we are redefining the future of healthcare. By prioritizing patient-centric solutions, we aim to address critical gaps in traditional pharmaceutical formulations, ensuring our innovations enhance the lives of patients and caregivers alike.

### Participants

**Presenter: Catherine Lee** - Director, TAHO Pharmaceuticals

## Vaccines: LimmaTech Biologics AG

14:30 - 14:45

Company Presentations: Coral 1

### Location: Coral 1

LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuncting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust company pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide.

### Participants

**Presenter: Franz-Werner Haas** - CEO, LimmaTech Biologics AG

## CNS/Neurology: Golgi Neurosciences Srl

14:30 - 14:45

Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

I would kindly ask you the opportunity to present Golgi Neurosciences, a company creator boutique fully dedicated to the development of small-molecule drugs for neurodegenerative diseases with high unmet medical need.

Golgi Neurosciences already holds an impressive portfolio of six participated biotech companies including Acousia Therapeutics (hearing loss), Rewind Therapeutics (demyelinating diseases), Libra Therapeutics (Amyotrophic Lateral Sclerosis), Muna Therapeutics (Alzheimer, Multiple Sclerosis and Parkinson), Lario Therapeutics (epilepsy and Parkinson) and Breye Therapeutics (retinopathies), which raised in total more than 200 million euros. Moreover, Golgi is developing a rich pipeline of innovative discovery programs, available for partnering or further company creation. During the last years, we have set up collaborations with renowned international research institutes and patient foundations which represent a valuable source of breakthrough science and innovative targets.

At the moment, we are working to launch our 7th NewCo, focused on astrocytes biology.

### Participants

**Presenter: Chiara Liberati** - Managing Director, Golgi Neurosciences Srl

## Company Presentations

14:45 - 15:00

Company Presentations: Coral 1

### Location: Coral 1

# SESSIONS

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Cardiovascular: Beijing Sungen Biomedical Technology Co., Ltd

14:45 - 15:00

Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

Beijing Sungen Biomedical Technology Co., Ltd is an innovation-driven, clinical-stage biotechnology company founded in 2018, dedicated to advancing human health through cutting-edge technologies. We are pioneering the development of First-in-Class (FIC) and Best-in-Class (BIC) antibody-based therapeutics, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs) and Antibody-oligonucleotide conjugates(AOCs). Supported by a team of dedicated researchers and management with successful biotechnology entrepreneur experiences, Sungen has developed major research and manufacturing platforms in-house, such as AI-powered drug discovery platform. We leverage our innovative technology platforms to transform targeted therapies, focusing on cardiovascular, tumor, and neurodegenerative diseases. It is our commitment to address critical unmet clinical needs and improve patient outcomes worldwide.

### Participants

**Presenter: Wei Zeng** - VP, Beijing Sungen Biomedical Technology Co., Ltd

## Pharma company presentation: Sanofi

15:00 - 15:15

Business of Biotech

### Location: Coral 2

#### Our Strategy

We're on course to transform the practice of medicine through breakthrough science and make a positive impact on our people and the communities we serve.

#### The Voices Behind Our Purpose

We chase the miracles of science to improve people's lives, and sometimes that means starting over with Plan B, Plan C, or even Plan Z. This film brings together the inner thoughts and ambitions of the people at Sanofi, who find inspiration from loved ones, motivation from families, and a united strength to push harder until we turn a corner.

#### Transforming The Practice of Medicine

Prioritization and focus are helping us unlock and maximize the potential of key medicines, vaccines, and self-care solutions for people, across our global business units: Specialty Care, Vaccines, General Medicines, and Consumer Healthcare.

We aim to become a leading company in immunology and positively impact millions of patients suffering from dermatological, respiratory, gastroenterological, and other immune-mediated diseases.

We earn every day our leadership in prevention by protecting half a billion people worldwide every year with our portfolio of vaccines and by leveraging our broad set of technology and manufacturing platforms, including in mRNA.

#### Advancing Breakthrough Science

We're strengthening our pipeline with a steady stream of potentially transformative therapies that could shift paradigms in treatment and prevention for people across the world.

We have a powerful toolbox of drug discovery platforms that allow us to break scientific ground in six therapeutic areas: Immunology and Inflammation, Oncology, Rare Diseases, Rare Blood Disorders, Neurology and Vaccines.

#### Driving Social Impact

The challenges facing society and the planet are becoming increasingly more complex. Shifting demographics, persistent inequalities in access to healthcare, and accelerating threats from climate change have motivated us to expand our commitments to society.

### Participants

**Presenter: Nizar El Murr** - Associate Director Search and Evaluation, Rare and Neurological Disorders, Sanofi

## Pharma company presentation: MSD

15:15 - 15:30

Business of Biotech

### Location: Coral 2

Our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we've brought hope to humanity through the development of important medicines and vaccines. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

### Participants

**Presenter: Daniel Marshall** - European Search & Evaluation, Business Development & Licensing, MSD

## Pharma company presentation: Servier

15:30 - 15:45

Business of Biotech

### Location: Coral 2

Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs.

The 21,900 employees of the Group are committed to this shared vocation, source of inspiration every day. As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 70% of its R&D budget to developing targeted and innovative therapies in oncology. Neuroscience is a future growth driver. In this area, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.

Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €5.9 billion in 2024.

Positioned as a Partner of choice:

- Private mid-size pharma company, ensuring continuity and long-term perspective in partnerships
- Global geographical footprint, with a presence in both established and emerging markets
- Science driven with strong R&D investment to build a high-quality and sustainable portfolio
- Fully integrated capabilities from research to commercialization
- Flexible and agile, we have over 60 strategic alliances with pharma companies, biotechs and academics worldwide to accelerate innovation.

### Participants

**Presenter: Anne Dagallier** - Business Development Director Global Lead Oncology, Servier



# SESSIONS

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Break and Breathe

15:30 - 15:45

Relax and Learn

### Location: Exhibit Hall Stage

Break, breathe, and thrive!

Take a break from your busy schedule to recharge and rejuvenate by immersing yourself in moments of tranquility and self-care.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Sustainability Focus Area: Social Responsibility

## Pharma company presentation: Almirall

15:45 - 16:00

Business of Biotech

### Location: Coral 2

Almirall is a leading global biopharmaceutical company focused on Medical Dermatology. Founded in 1944 and with headquarters in Barcelona (Spain), our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life".

Through pharmaceutical innovation, investment in R&D and strong commitment to global healthcare partnerships, we develop and commercialize solutions with specific focus on dermatological diseases such as psoriasis.

### Participants

**Presenter: Dmitry Tsay** - Licensing Transactions Director, Almirall

## Couture for the mind: Innovations in CNS

16:00 - 16:45

Therapeutic Insights

### Location: Coral 2

As neurological disorders continue to evolve, this session explores the cutting-edge innovations, transformative breakthroughs and latest deals in the field to address the complex challenges in neurology and uncover the strategic opportunities that lie ahead.

### Participants

**Moderator: Barnaby Pickering** - Freelance Writer, Account Executive, RHA Communications

**Panelist: Laura Faravelli** - VP Business Development, Newron Pharmaceuticals

**Panelist: Blake Hopiavuori** - Associate Director, Abbvie

**Panelist: Paul Little** - CEO, Vesper Bio

**Panelist: Prabhu Velusami** - Senior Director, Early Innovation Partnering, Johnson & Johnson

## On-trend strategies: Navigating the biopharma services landscape

16:00 - 16:30

Ecosystem Innovation

### Location: Exhibit Hall Stage

As the biopharma services landscape continues to evolve, this session highlights the emerging trends, key challenges and innovative strategies for optimizing partnerships, and provides insights into improving efficiency and streamlining operations for service providers to thrive in a competitive market.

### Participants

**Moderator: Millie Nelson** - Editor of BioXconomy, Informa

**Panelist: Igor Fisch** - CEO, NewBiologix

**Panelist: Darren Gibson** - Executive Director, Frontier Science (Scotland) Limited

**Panelist: Heiko Richtzenhain** - Head of Sales and Business Development, Menarini Biotech

**Panelist: Nikola Strumberger** - SVP Commercial Operations Ergomed Clinical Research, Ergomed

## The art of storytelling in collaboration with the YVC Collective: 'Narrative vs science - How can young entrepreneurs and investors empower biotech storytelling?

16:30 - 17:15

Business of Biotech

### Location: Coral 3

European biotechs often encounter difficulties in crafting narratives that capture investor interest as effectively as their US counterparts.

Opening questions:

· How can young CEOs cultivate storytelling skills that resonate with both European and global investors?

· How can young investors support biotechs to craft authentic narratives without losing scientific rigor?

### Participants

**Moderator: Philip Brainin** - Associate, Sound Bioventures

**Moderator: Catello Somma** - Partner, Seroba

**Panelist: Mary Clark** - CEO, Optimum Strategic Communications

**Panelist: Regina Hodits** - Managing Partner, Wellington Partners

**Panelist: Juliette Lee** - VP, EQT Life Sciences

## Rare & Orphan Diseases: Pharming Group N.V.

16:30 - 16:45

Company Presentations: Coral 1

### Location: Coral 1

Pharming is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patient.

### Participants

**Presenter: Jonathon Fendelman** - Business Development, Pharming Group N.V.

# SESSIONS

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Rare & Orphan Diseases: TargED Biopharmaceuticals B.V.

16:45 - 17:00

Company Presentations: Coral 1

### Location: Coral 1

TargED Biopharmaceuticals B.V. is a Netherlands based biotechnology company developing first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using single-chain antibodies ("VhH") to deliver enzymes to sites of thrombosis, enabling 'targeted' thrombolysis. The company's lead compound, TGD001, is currently in development for the treatment of thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

### Participants

**Presenter: Kristof Vercruysse** - CEO, TargED Biopharmaceuticals B.V.

## Young innovators reception in collaboration with the YVC Collective

17:00 - 18:00

Ecosystem Innovation

### Location: Exhibit Hall Stage

## Vaccines: BiOMViS Srl

17:00 - 17:15

Company Presentations: Coral 1

### Location: Coral 1

BiOMViS Srl, a Biotech Company located at the Toscana Life Sciences Scientific Park (Siena, IT), has developed a unique platform technology for the design of vaccines against infectious diseases and for cancer immunotherapy. The platform is based on Outer Membrane Vesicles (OMVs) released in the culture supernatant by proprietary non-pathogenic E. coli strains. Using patented synthetic Biology strategies, the OMVs can be decorated with virtually any antigen of bacterial and viral origin. Once purified using extremely simple and inexpensive procedure, the OMVs are ready-to-use vaccines, which do not require the addition of any other component before formulation. Thanks to their potent immunostimulatory activity, BiOMViS is also exploiting its OMVs in cancer immunotherapy both as personalized vaccines, once properly engineered with cancer neo-epitopes, and as vaccines broadly applicable in most solid tumors using in situ vaccination. BiOMViS has been exploiting its platform technology for the design of a variety of vaccines against important human pathogens, including: Staphylococcus aureus, Streptococcus pyogenes (Group A Streptococcus), Neisseria meningitidis Group B (MenB), Chlamydia, human Papilloma Virus, Coronavirus, Dengue Virus. Most of these vaccine candidates have completed the pre-clinical phase and are now ready to move to development. BiOMViS' business model is twofold. 1) the Company is seeking Pharma and Biotech Companies interested to test the BiOMViS' platform for their own vaccine pipeline and eventually to establish license agreements restricted to the specific vaccine of interest. 2) BiOMViS is willing to establish agreements with third Parties interested in developing some of the vaccines included in the list of BiOMViS' pipeline.

### Participants

**Presenter: Guido Grandi** - Professor, BiOMViS Srl

## Antibodies: KisoJi Biotechnology Inc.

17:15 - 17:30

Company Presentations: Coral 1

### Location: Coral 1

KisoJi is a Canadian biotechnology company that deploys the latest scientific and AI tools to conduct therapeutic antibody discovery in a fundamentally new way.

KisoJi has developed a multi-species transgenic mouse to generate highly diverse single domain antibodies, as well as a modular multi-specific antibody scaffold with high stability and productivity. Most recently, KisoJi has used advanced AI tools to visualise the universe of all antibodies against a target in order to uncover novel biology and new therapeutic antibody capabilities for its partners and its own pipeline.

### Participants

**Presenter: Gordon Ngan** - VP, Business Development, KisoJi Biotechnology Inc.

## Exhibit Hall Reception

18:00 - 21:00

### Location: Exhibit Hall

**Time:** 18:00 – 21:00

Join the fun and sing your heart out with Karaoke on the Exhibit Hall Stage from 19:00 - 21:00!

### Exhibitors:

- Booth 6 - Prague.bio
- Booth 78 - Citeline
- Booth 79 - Bayern International
- Booth 102 - Copenhagen Capacity
- Booth 113 - Health~Holland
- Booth 133 - Swiss Biotech

# SCHEDULE

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

TIME	RELAX AND LEARN	RELAX AND LEARN.	BUSINESS OF BIOTECH	LUNCH	THERAPEUTIC IN-SIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
07:00	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)
08:00	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:30 - Buzz Session: Winning presentations, influencing partnerships  08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)	08:00 - Partnering: one-to-one meetings (9:00 - 18:30 CET)
09:00	09:30 - partneringONE essentials workshop							
10:00			10:00 - Opening remarks  10:30 - Italian roots, global reach: Biotech investment insights - a dynamic conversation with Graziano Seghezzi and Francesco De Rubertis					

# SCHEDULE

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	RELAX AND LEARN	RELAX AND LEARN.	BUSINESS OF BIOTECH	LUNCH	THERAPEUTIC IN-SIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
11:00			11:30 - Deals in vogue: Navigating M&A and business development in a shifting global landscape					
12:00	12:00 - partneringONE power up workshop			12:00 - Lunch				
13:00					13:00 - Seamless advancements: Paving the future of cell and gene therapy		13:00 - Cell & Gene Therapies: Accelerated Biosciences Corp. 13:15 - Cell & Gene Therapies: AAVner-Gene Inc. 13:30 - Cell & Gene Therapies: Kolon Life Science 13:45 - Cell & Gene Therapies: Basecamp Research	13:00 - CNS/Neurology: Neurochlore 13:15 - CNS/Neurology: Vesper Bio 13:30 - CNS/Neurology: Owl Therapeutics 13:45 - CNS/Neurology: Lario Therapeutics Ltd.

# SCHEDULE

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	RELAX AND LEARN	RELAX AND LEARN.	BUSINESS OF BIOTECH	LUNCH	THERAPEUTIC IN-SIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
14:00			14:00 - Deconstructing breakthroughs: Unpacking lessons from Alys Pharmaceuticals on advancing Immuno-Dermatology				14:00 - Autoimmune/Inflammation: Canopy Immuno Therapeutics 14:15 - Autoimmune/Inflammation: Insilico Medicine 14:30 - Vaccines: LimmaTech Biologics AG 14:45 - Company Presentations	14:00 - CNS/Neurology: Tonix Pharmaceuticals Holding Corp. 14:15 - Cardiovascular: TAHO Pharmaceuticals 14:30 - CNS/Neurology: Golgi Neurosciences Srl 14:45 - Cardiovascular: Beijing Sungen Biomedical Technology Co., Ltd
15:00	15:30 - Break and Breathe		15:00 - Pharma company presentation: Sanofi 15:15 - Pharma company presentation: MSD 15:30 - Pharma company presentation: Servier 15:45 - Pharma company presentation: Almirall					

# SCHEDULE

DAY 1 - 17/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	RELAX AND LEARN	RELAX AND LEARN.	BUSINESS OF BIOTECH	LUNCH	THERAPEUTIC IN-SIGHTS	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
16:00			16:30 - The art of storytelling in collaboration with the YVC Collective: 'Narrative vs science - How can young entrepreneurs and investors empower biotech storytelling?		16:00 - Couture for the mind: Innovations in CNS	16:00 - On-trend strategies: Navigating the biopharma services landscape	16:30 - Rare & Orphan Diseases: Pharming Group N.V.  16:45 - Rare & Orphan Diseases: TargED Biopharmaceuticals B.V.	
17:00						17:00 - Young innovators reception in collaboration with the YVC Collective	17:00 - Vaccines: BiO-MViS Srl  17:15 - Antibodies: KisoJi Biotechnology Inc.	
18:00	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception	18:00 - Exhibit Hall Reception

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Rise & Run

06:30 - 07:30

Enjoy a social run at an easy pace around the beautiful city of Milan, led by local trainers.

**WHEN:** Tuesday, March 18, 06:30

**MEETING POINT:** In front of the Melia Milano Hotel, Via Masaccio 19, Milan

**DURATION:** 60 min, 06:30–07:30

Registration in advance is encouraged! [SIGN UP HERE](#)

## Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)

08:00 - 08:30

Location: **Allianz MiCo**

Light Breakfast: **served until 10:45**

## Partnering: one-to-one meetings (8:00 - 17:00 CET)

08:30 - 08:45

One-to-one meetings at BIO-Europe Spring will be scheduled during the hours below:

Meetings on this day will start at 8:00 - 17:00 CET.

## YesMilano Breakfast Panel

08:45 - 09:20

Ecosystem Innovation

Location: Exhibit Hall Stage

### Participants

**Moderator: Marica Nobile** - Director, Federchimica Assobiotech

**Panelist: Luigi Naldini** - Director, SR-TIGET, San Raffaele Telethon Institute for Gene Therapy

**Panelist: Matteo Giovanni Della Porta** - Director, Leukemia Unit, Humanitas Research Hospital

**Panelist: Marco Baccanti** - Director, FITT Foundation

**Panelist: Marco Gorini** - Head of Digital Health and Innovation, AstraZeneca

## Market spotlight: How is innovation from China and Asia reshaping global biopharma?

09:30 - 10:15

Business of Biotech

### Location: Coral 3

As China and Asia emerge as global powerhouses in biopharma innovation, the region's influence is reshaping the industry's dynamics. This panel will explore the rise of cutting-edge therapies, groundbreaking research, and transformative business models originating from the East. With a focus on licensing strategies, the emergence of new biotechs (newcos), and an increasing volume of cross-border deals, we'll examine how these trends are driving partnerships, altering the competitive landscape, and accelerating access to innovation.

### Participants

**Moderator: Robert Darwin** - Private Equity/Life Sciences & Healthcare Partner, Sidley Austin LLP

**Panelist: Jesus Baena** - BD&L Transactions Oncology Director, Novartis

**Panelist: Tomas Landh** - Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation, Novo Nordisk

**Panelist: William Pay** - Venture Partner, Pappas Capital

**Panelist: Nerida Scott** - VP, Head of Innovation EMEA, Johnson & Johnson

## Oncology: Immuneering Corporation

09:30 - 09:45

Company Presentations: Coral 1

### Location: Coral 1

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company's lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company's development pipeline also includes several early-stage programs.

### Participants

**Presenter: Harold Brakewood** - CBO, Immuneering Corporation

## Oncology: AmMax Bio, Inc.

09:45 - 10:00

Company Presentations: Coral 1

### Location: Coral 1

AmMax Bio ("AmMax") is a venture-backed clinical-stage oncology company focused on the development of first-in-class therapeutics to address significant unmet needs and large market potential. It was founded in 2020 out of a partnership with Amgen wherein AmMax gained an exclusive worldwide right to AMB-066. Amgen has a minority stake in AmMax.

AmMax has an experienced management that has a proven track record and collectively covers the entire spectrum of drug development and commercialization across multiple modalities. It is led by Larry Hsu, Ph.D., who founded and led the successful IPO of Impax Laboratories on the NASDAQ with over \$3 billion in market cap.

Leveraging its translational science expertise and clinical development experience, AmMax has built a robust portfolio. At the core of its portfolio are AMB-066, in Phase 2, for colorectal cancer minimal residual disease (CRC MRD) and AMB-104, an antibody-drug conjugate (ADC), for acute myeloid leukemia (AML) and solid tumors.

AMB-066 has the potential to be the first-to-market treatment for CRC MRD, an indication representing potentially a \$6 billion market in the US and 5EU. CRC MRD is diagnosed by positive ctDNA and the lack of radiographic evidence of tumor in patients post surgery with/without peri-operative therapies. These patients are at a much higher risk to develop metastasis, typically within 12 months, and are currently without treatment options.

AMB-104 is the only ADC in active development that targets colony stimulating factor 1 receptor (CSF1R) to address the significant unmet needs in AML. AMB-104's unique mechanism of action also renders it the potential to target a wide range of solid tumors. Even with several approved therapies, AML is poorly served: ~20-40% of newly diagnosed don't achieve CR1 and > 50% of CR1 relapse within 3 years; Significant portions of patients have no actionable biomarkers; Existing therapies in the R/R setting have limited efficacy with OS <10% at 3 years.

### Participants

**Presenter: Laura Zhu** - CBO, AmMax Bio, Inc.

# SESSIONS

## DAY 2 - 18/03/2025

BIO-Europe Spring  
THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

### A work of art: Success as a first-time launcher in Europe

10:00 - 10:45  
Ecosystem Innovation

#### Location: Exhibit Hall Stage

Increasingly, smaller biotech companies are launching their new drugs themselves, rather than relying on large pharmaceutical companies to make this happen for them. How can they get it right the first time?

Managers of biotech companies with a drug in late-stage clinical development face a challenge: as their asset progresses well in clinical trials, they need to decide whether to license it out or market it themselves. In the European Union, the number of companies that market only a single pharmaceutical product has increased from four in 2014 to 33 in 2024. This panel will discuss the deciding factors for successfully marketing a product independently in Europe.

What are the pros and cons of launching a product oneself instead of licensing it out? Which products are better suited for out-licensing? How does the EMA support

biopharmaceutical companies that are applying for marketing authorization for a pharmaceutical product for the first time? What role does the harmonized HTA assessment procedure play in market access and reimbursement, and how can it be aligned with marketing authorization?

#### Participants

**Moderator: Tilo Mandry** - Lead International Liaison Manager, IGES Institut GmbH

**Panelist: Thomas Ballotti** - Scientific Officer, European Medicines Agency

**Panelist: Delphine Bourdon** - VP, Head of International Finance, Blueprint Medicines

**Panelist: Daniel Ghysels** - VP, Commercial Europe, Immunocore

### Oncology: Precirix

10:00 - 10:15  
Company Presentations: Coral 1

#### Location: Coral 1

Precirix is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies (sdAb) labelled with radiometals. Our precision radiometal sdAb platform technology allows us to rapidly and reliably generate highly precise TRT for any cancer surface target, with unparalleled tumor retention, rapid blood clearance and minimized off-target effects

#### Participants

**Presenter: Tom Plitz** - CEO, Precirix

### Oncology: Tempus AI

10:15 - 10:30  
Company Presentations: Coral 1

#### Location: Coral 1

Tempus aims to transform precision medicine by delivering Intelligent Diagnostics, harnessing AI to elevate laboratory testing in healthcare. These diagnostics enhance accuracy by connecting lab results directly to each patient's clinical data, creating personalized insights that guide treatment options, drug recommendations, trial selections, and clinical care pathways tailored to individual patient profiles. At the core is the Tempus Platform, which integrates an advanced technology framework with an operating system that liberates healthcare data from traditional silos, making it actionable for physicians and researchers. With one of the largest global libraries of clinical and molecular oncology data, Tempus seeks to embed AI, including generative AI, across diagnostics to support data-driven decision-making. This platform empowers healthcare professionals to provide highly personalized care, leveraging a robust dataset that informs clinical insights and optimizes patient outcomes.

Recent advancements in cloud computing, imaging technologies, large language models, and cost-efficient molecular profiling-paired with an increasingly digital healthcare ecosystem-have created a ripe environment for scaled AI implementation. Despite the availability of healthcare data, many practitioners remain limited in their ability to apply it meaningfully. Most traditional diagnostic approaches focus on isolated data points, like specific biomarkers, rather than a comprehensive, integrated clinical profile necessary for precision care.

Tempus addresses this gap by establishing seamless data channels between providers, allowing a continuous flow of information across healthcare settings. This infrastructure enables real-time data exchange, empowering diagnostic labs, life sciences, and clinical institutions to access actionable insights. The Tempus Platform is actively deployed across the U.S., primarily in oncology, and is expanding into neuropsychology, radiology, and cardiology.

#### Participants

**Presenter: Shyam Khatau** - VP, Life Sciences, Tempus AI

### The AI edit: What's the real deal?

10:30 - 11:15  
Business of Biotech

#### Location: Coral 2

Is AI merely a buzzword or is it truly transformative? This session examines the role of AI in biotech and pharma. Explore how AI is improving the economics of R&D, addressing integration challenges and gradually reshaping drug development. Through real-world examples, gain insights into the current influence of AI and its potential long-term impact on drug discovery and the future of the life science ecosystem.

#### Participants

**Moderator: Hubert Birner** - Managing Partner, TVM Capital

**Panelist: Michelle Chen** - CBO, Insilico Medicine

**Panelist: Nikolaus Krall** - Managing Director, Exscientia GmbH

**Panelist: Miha Stajdohar** - CTO and Co-founder, Genialis

**Panelist: Friedrich von Bohlen** - CEO, Molecular Health

### Oncology: FoRx Therapeutics AG

10:30 - 10:45  
Company Presentations: Coral 1

#### Location: Coral 1

FoRx Therapeutics develops innovative small molecule inhibitors that target DNA Damage Response (DDR) pathways for anti-cancer therapy. Since DNA damage is a hallmark of cancer and requires continuous repair, the company's approach is to inhibit distinct DDR proteins and deprive cancer cells of their repair capability, resulting in the cells' death.

The company's pipeline encompasses novel, first-in-class as well as differentiated, best-in-class programs for oncology indications. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which is being evaluated in IND enabling studies. The company is currently in the process of transitioning to a clinical organization and has recruited a CMO to advance FORX-428 through clinical studies. FoRx Therapeutics has 15 employees and is backed by EQT Life Sciences (formerly LSP), M Ventures, Omega Funds, Novartis Venture Fund and Pfizer Ventures, having raised a total of 30 million CHF in Seed Financing and 10 million CHF in Bridge Financing.

#### Participants

**Presenter: Tarig Bashir** - CEO, FoRx Therapeutics AG



# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Immunology: Graph Therapeutics

10:45 - 11:00

Company Presentations: Coral 1

### Location: Coral 1

Graph Therapeutics (Graph) is an AI-driven precision immunology startup developing a unique target validation platform that integrates multi-modal ex vivo perturbation screening with matched molecular profiling in primary patient samples. Our platform addresses a critical bottleneck in immune disease drug development - the lack of robust, clinically realistic target validation prior to expensive asset development. By bringing forward key elements of translational validation to the discovery phase, we can significantly reduce the current ~90% failure rate of clinical trials.

Our approach uniquely combines functional validation through siRNA knockdowns in disease-relevant primary cell models with matched multi-modal profiling at single-cell resolution, capturing morphology, transcriptomics, and protein expression in the same cells. This is integrated with clinical benchmarking through systematic comparison to standard of care drug responses in a lab-in-the-loop framework that continuously incorporates validation data to improve target predictions.

Graph builds on a decade of experience pioneering similar approaches in oncology, including development of the only ex vivo precision medicine platform validated through prospective interventional trials. We are currently funded by leading deep tech investors including Merantix Ventures, having raised €3.1M in pre-seed. Graph is actively developing core target validation capabilities alongside our sterile inflammation discovery program, positioning us to rapidly validate novel therapeutic targets as they emerge from our platform. Our goal is to build the industry's most comprehensive validation stack for immune disease targets, enabling better and faster therapeutic development for millions of patients with immune-mediated diseases.

### Participants

**Presenter: Gregory Vladimer** - Co-Founder and CEO, Graph Therapeutics

## Immuno-Oncology: Immunos Therapeutics

11:00 - 11:15

Company Presentations: Coral 1

### Location: Coral 1

ImmunOs Therapeutics AG has developed a proprietary human leukocyte antigen (HLA)-based platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease. Its lead asset IOS-1002 is in Phase I clinical trial in solid cancer. ImmunOs is backed by an international consortium of top-tier investors, including Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and Doublepoint Ventures.

### Participants

**Presenter: Hilmar Ebersbach** - CSO, Immunos Therapeutics

## Break and Breathe

11:00 - 11:15

Relax and Learn

### Location: Exhibit Hall Stage

Break, breathe, and thrive!

Take a break from your busy schedule to recharge and rejuvenate by immersing yourself in moments of tranquility and self-care.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Sustainability Focus Area: Social Responsibility

## Immuno-Oncology: IO Biotech

11:15 - 11:30

Company Presentations: Coral 1

### Location: Coral 1

IO Biotech is transforming the treatment of cancer patients through the discovery and development of novel immune-modulating therapeutic vaccines, including the most clinically advanced therapeutic cancer vaccine program in development for 1st line patients with advanced melanoma

Corporate Positioning Statement:

Founded in 2014, IO Biotech (Nasdaq: IOBT) is a clinical-stage biopharmaceutical company dedicated to transforming the lives of cancer patients through novel therapeutic vaccines. IO Biotech is developing immune-modulating vaccines that turn the tumor microenvironment hostile to cancer and immune-suppressive cells. Early data suggests that these vaccines have the potential to improve patient outcomes without adding systemic toxicity. IO Biotech's lead candidate, IO102-IO103, is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the TME by stimulating activation and expansion of T cells against IDO+ and PD-L1+ cells. IO102-IO103 is currently in a pivotal Phase 3 trial for advanced melanoma, with the primary endpoint expected to read out in the first half of 2025, and in Phase 2 trials for other advanced solid tumors and for resectable solid tumors. The U.S. Food and Drug Administration granted IO102-IO103 a breakthrough therapy designation for the treatment of advanced melanoma in combination with pembrolizumab in 2020. The company is headquartered in Copenhagen, Denmark with U.S. headquarters in New York.

### Participants

**Presenter: Faical Miyara** - CBO, IO Biotech

## Sketching the future of biotech investment with Lilly Ventures

11:30 - 12:00

Business of Biotech

### Location: Coral 2

In this fireside chat with Laura Lane, Head of European Investment at Lilly Ventures, we will delve into the dynamic world of biotech investment. This session will cover the importance of new science and emerging entrepreneurs, the critical role that venture capital plays in bringing innovation to patients, and how biotech companies can get that all important first meeting.

### Participants

**Moderator: Jo Shorthouse** - Executive Editor, In Vivo

**Panelist: Laura Lane** - VP Lilly Ventures , European Head, Eli Lilly & Company

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Designing tomorrow's biotech: The interdependent ecosystem of therapeutic areas, research collaborators, and innovative funding models

11:30 - 12:00

Ecosystem Innovation

**Location:** Exhibit Hall Stage

The biotech industry is rapidly evolving, with new therapeutic areas and innovative funding models emerging to drive advancements in healthcare. This panel explores the interdependent ecosystem of biotech, research collaborators, and funding models, and how they are revolutionizing the business of biotech. We examine the latest trends in therapeutic areas, including gene therapy, immunotherapy, and precision medicine, and how they are transforming drug development. We also explore the role of research collaborators, such as CROs, in driving innovation and accelerating drug development. Finally, we discuss the latest funding models, including venture capital, public-private partnerships, and crowdfunding, and how they are changing the way biotech raise capital and bring new therapies to market. By examining the interplay between these key elements, we provide insights into the future of the biotech industry and the potential for continued innovation in healthcare.

### Participants

**Moderator: Will Maier** - Senior Vice President, Drug Development Solutions, ICON Biotech

**Panelist: Graham Mills** - Principal, Abingworth LLP

**Panelist: Charles Sermon** - General Counsel and Business Development, Mereo BioPharma

**Panelist: Tom Shepherd** - CEO, Captor Therapeutics

## Immuno-Oncology: Oncolys BioPharma

11:30 - 11:45

Company Presentations: Coral 1

**Location:** Coral 1

Oncolys aims to contribute to the advancement of medical science, by bringing innovation to the existing treatments for "cancer" and "serious infectious diseases", leveraging our virology-based new drug discovery technologies.

Especially in the oncology area, Oncolys develops OBP-301 (Telomelysin). OBP-301 is a gene-modified oncolytic adenovirus in which selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. Oncolytic adenovirus has much potential for cancer immunotherapy because its viral replication is highly immunogenic, and oncolysis induced by such virus releases tumor antigen and provides costimulatory danger signals. From the result of phase 1 clinical study in the US, Telomelysin showed abscopal effect, which non-injected tumor as well as injected tumor was regressed in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site. Oncolys BioPharma has completed a pivotal study of OBP-301 in Japan in Esophageal cancer combination with RT, and planning NDA in 4Q2024-1Q2025 (JP). OBP-301 clinical trials are also ongoing for Head and neck cancer, TNBC, and HCC.

Oncolys USA our fully owned subsidiary, was established in 2016 and plays a crucial role in expanding our reach within the US market, facilitating clinical trials and fostering collaborations within leading research institution. Oncolys USA is conducting several early phase I/II studies in Esophageal cancer Gastric cancer and is planning to initiate pivotal phase 2/3 study in esophageal cancer as first indication for approval in the US. In addition, Oncolys USA is planning on expanding the label of OBP-301 in the US to Head and Neck cancer and TNBC. Oncolys USA will have exclusive rights for OBP-301 and our second-generation oncolytic virus, OBP-702 within 2025

### Participants

**Presenter: Talia Biran** - President, Oncolys BioPharma

## Immuno-Oncology: Altevax

11:45 - 12:00

Company Presentations: Coral 1

**Location:** Coral 1

Altevax is a French clinical-stage biotechnology company pioneering first-in-class immunotherapies using synthetic melanin to create biological nanoparticles that carry specific antigens. This innovative approach induces a robust and targeted immune response against tumors. Altevax's lead program focuses on glioblastoma (GBM), with a First-in-Human trial launched in November 2024.

Our proprietary technology serves as a versatile vaccine platform with potential applications across a wide range of cancers. Preclinical proof-of-concept studies have demonstrated the platform's efficacy in multiple animal models. By leveraging synthetic melanin as a carrier, Altevax enhances antigen presentation to the immune system, effectively activating T lymphocytes for a specific anti-tumor response.

Altevax targets TERT, an antigen highly expressed in glioblastoma cancer cells. The melanin-TERT nanoparticle vaccine stimulates a strong immune response, addressing the challenges posed by weakly immunogenic self-antigens by incorporating them into the melanin nanoparticle.

Altevax's proprietary platform represents a groundbreaking advancement in cancer immunotherapy. With its potential to address high unmet medical needs, this novel approach offers new hope for transforming treatment paradigms and improving outcomes for cancer patients.

### Participants

**Presenter: Batoul Farhat** - Head of Business Development, Altevax

### Lunch

12:00 - 14:00

Lunch

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Brushing up on biotech financing: How important is venture debt?

12:00 - 12:25

Ecosystem Innovation

**Location:** Exhibit Hall Stage

The European biotech sector stands at a pivotal moment, balancing groundbreaking innovation with persistent financing challenges. Despite thriving advancements in therapeutics, diagnostics, and platform technologies, securing capital—especially during the critical "valley of death" between early-stage R&D and commercialization—remains a significant hurdle. Recent discussions on global biotech financing trends have highlighted the cautious IPO market in Europe and the evolving priorities of venture capitalists and pharmaceutical companies. However, equity financing is not the only available option. Venture debt has emerged as a crucial non-dilutive funding mechanism, enabling biotech companies to extend cash runways, achieve key clinical milestones, and navigate funding gaps between equity rounds. As the sector seeks sustainable growth, strategic deployment of venture debt may prove essential in bridging financial shortfalls and accelerating innovation.

### Participants

**Moderator: Mike Ward** - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

**Panelist: Gergely Krajcsi** - Senior Investment Officer for Life Science & Biotech Growth Finance & Venture Debt, European Investment Bank

## Immunology: Ziphius NV

12:00 - 12:15

Company Presentations: Coral 1

**Location:** Coral 1

Ziphius, a preclinical biotech company founded in 2019, has developed a proprietary self-amplifying RNA (saRNA) and Lipid Nanoparticle (LNP) platform, which enables higher protein/antigen expression at lower doses. This results in a more potent and longer-lasting immune response—both humoral and cellular—while enhancing safety through reduced toxicity and extended dosing intervals.

Our current pipeline showcases strategic developments in infectious diseases, rare diseases, and oncology. Having raised \$43 million, we are now conducting studies in higher species as we prepare for clinical trials. With a dedicated team of 65 professionals based in Belgium and the US (New York), Ziphius is committed to developing first- and best-in-class RNA medicines.

### Participants

**Presenter: Damien Dessis** - CBO, Ziphius NV

## Company presentations

12:15 - 12:30

Company Presentations: Coral 1

**Location:** Coral 1

## The perfect fit: Why Australia is a go-to destination for clinical trials

12:30 - 13:00

Ecosystem Innovation

**Location:** Exhibit Hall Stage

Discover how your organisation can benefit from partnering with Australia's world-leading clinical trial ecosystem.

Sector leaders will discuss why Australia is the international home of high-quality, efficient, cost-effective clinical trials.

The panel will outline Australia's efficient approvals process, IND-free regulatory framework, world-class clinical workforce and facilities, high-quality FDA and EMA recognised data outputs, genetically diverse participant recruitment pool, robust IP protections, and generous R&D tax incentives.

### Participants

**Moderator: Libby Kruse** - Trade Manager, Health and Life Sciences, The State Government of Victoria Australia

**Panelist: Angela Luttick** - EVP, Commercial, 360biolabs

**Panelist: Pavel Reddy** - Director, GLOBAL R&D

**Panelist: Megan Robertson** - Director of Research, St Vincent's Hospital Melbourne

**Panelist: Sam Vohra** - Founder & CEO, AVION Full Service CRO & Imaging Specialists

## Day in the life of an experienced dealmaker

13:00 - 13:45

Business of Biotech

**Location:** Coral 3

Join leading pharma and venture investors and unravel strategies for navigating the current dealmaking landscape. Uncover trends, actionable insights, and key considerations for building successful partnerships, along with the tools to thrive in today's competitive environment to drive impactful collaborations.

### Participants

**Moderator: Evonne Sepsis** - Founder and Managing Director, ESC Advisors

**Moderator: Anton Gueth** - Managing Director, EVOLUTION Life Science Partners

**Panelist : Hakan Goker** - Managing Director, M Ventures

**Panelist: Jenny Laird** - VP Search & Evaluation, Eli Lilly and Company

**Panelist: Monika Vnuk** - SVP, Global Partnering & Business Development, Sanofi

## Drug Discovery & Development: Rejuvenate Biomed

13:00 - 13:15

Company Presentations: Coral 1

**Location:** Coral 1

Rejuvenate Biomed is an AI-enabled, clinical-stage biotech company decoding the biology of aging to develop safe, synergistic combination therapeutics that holistically address the root causes of age-related diseases. By targeting multiple disease pathways simultaneously, the company aims to provide more effective treatments that can alter the course of disease. Utilizing two clinically validated proprietary drug discovery platforms, AI-enabled in silico CombinAge™ and in vivo CelegAge™, Rejuvenate Biomed has generated a robust pipeline of five unique combination drugs targeting different age-related diseases. These conditions range from neuromuscular, musculoskeletal, metabolic, neurodegenerative and immunology related indications. Its lead Phase 2 asset, RJx-01, has already demonstrated significant potential in treating sarcopenia. The company's disease agnostic drug discovery platforms continue to provide insight by uncovering hidden patterns in biomedical graphs into future therapeutics, driving pipeline growth and potential partnerships. Rejuvenate Biomed is dedicated to promoting healthy aging.

### Participants

**Presenter: Ann Belien** - Founder and CEO, Rejuvenate Biomed

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Metabolic Diseases: MitoRx Therapeutics Limited

13:00 - 13:15

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

MitoRx Therapeutics is a preclinical stage first-in-class biotech developing mitochondrial-targeted small molecules in obesity-related disorders

MitoRx's novel small molecules combine strong muscle preservation activity with anti-obesogenic properties, featuring a mechanism of action differentiated from any other small molecule in the clinic or on the market. MitoRx is raising a Series A to take its approach forward through IND to a novel phase 1/2a part c in obese patients with underlying disease, with a trial design generating early non-invasive MRI imaging evidence of efficacy in muscle and liver.

In results to be presented at BIO-Europe Spring 2025, MitoRx will demonstrate that their pioneering approach restoring sulfide-signal transduction in the diet-induced obesity model drive fat loss while preserving muscles and therefore represents a new class of weight loss medicine. This avoids the relentless agonism of GLP-1 that causes gastrointestinal side effects and loss of lean mass, leading to poor compliance and cessation of therapy which blights incretin medicines, offering a safer alternative as a monotherapy in sarcopenic obesity including many T2D patients as well as patients who have ceased GLP-1 therapy.

In summary, while incretins are anti-obesogenic and cause muscle wasting, MitoRx's novel approach is anti-obesogenic and is muscle preserving.

### Participants

**Presenter: Jonathan Rees** - CEO, MitoRx Therapeutics Limited

## Drug Discovery & Development: Pioneering Medicines

13:15 - 13:30

Company Presentations: Coral 1

### Location: Coral 1

Pioneering Medicines is Flagship's in house drug discovery and development unit. Pioneering Medicines was formed to accelerate the creation of novel therapeutics and maximize the value creation and patient impact of Flagship's first-in-category bioplatfroms. We're here to make new medicines for patients, sooner.

Our team of drug development experts creates new therapeutics built from Flagship's innovative bioplatfroms and novel modalities. More than 40 companies across the Flagship ecosystem are pioneering innovative platform technologies to address major challenges in human health. Pioneering Medicines explores and identifies new product concepts and then works jointly with Flagship's companies to form integrated teams that advance medicines through robust discovery and early clinical development.

Pioneering Medicines also partners with external collaborators across biopharma throughout our R&D process. We apply our unique approach to the R&D priorities of our partners through highly co-creative relationships that draw on the expertise of our respective teams. Pioneering Medicines leads Flagship's Innovation Supply Chain Partnerships with Novo Nordisk, Pfizer and GSK to speed innovation in drug development and bring novel therapies to patients. The team also leads a partnership with the Cystic Fibrosis Foundation to develop therapeutics that address the unmet needs of people living with cystic fibrosis.

### Participants

**Presenter: Fang Zhang** - VP, Business Development, Pioneering Medicines

## Metabolic Diseases: Ciloa

13:15 - 13:30

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

ADIPONECTIN, THE PERFECT CO-AGONIST TO ENHANCE GLP-1RA THERAPEUTIC EFFECTS ON OBESITY AND DIABETES.

Ciloa has developed a breakthrough solution for obesity, diabetes, MASH and metabolic diseases based on adiponectin, renowned in particular for its anti-inflammatory, anti-oxidative stress and insulin-sensitizing properties. As a pioneer in EVs bioengineering, we have succeeded for the first time in stabilizing highly multimerized and functional adiponectin by anchoring it to EVs. In DIO/MASH animal model, this adiponectin acts synergistically with the GLP-1R agonist to stimulate weight loss, to enhance dramatically fat clearance in all organs tested and induce full recovery of insulin sensitivity, while preserving muscle mass.

In parallel, we have also overcome the challenges of biotherapeutic EV production: in 2023, we produced 20 batches of high quality bioengineered EVs in our cleanroom from over 100 liters of cell culture.

### Participants

**Presenter: Robert Z. Mamoun** - CEO, Ciloa

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Drug Discovery & Development: InnoMedica Holding AG

13:30 - 13:45

Company Presentations: Coral 1

### Location: Coral 1

#### Company and Financials

- Company: InnoMedica Holding AG, fully owned subsidiaries, Switzerland/Germany
- Financing: a total of 13 public capital increases, 1,555 shareholders, CHF 80m raised
- IPO: SIX Swiss Exchange or Nasdaq in 2027 after breakeven, IFRS reporting since 2019
- Current Cash burn: CHF 0.8m per month
- Cash at the end of 2024: CHF 11m
- Largest shareholder: Dr. Peter Halbherr, 18 percent
- Shareholder pool: a group of five entities with 36 percent shareholdings
- Financing needs: CHF 38m financing gap until breakeven

#### Technology

Newly developed lipid nanoparticle platform capable of efficient site-directed drug delivery, reaching unprecedented efficacy-toxicity profiles for existing and new molecular entities. The in-house manufacturing technology enables InnoMedica to produce a multiverse of highly functional lipid nanoparticles with the world's smallest diameter of 35 nanometers.

#### Clinical Assets

1. Talineuren: first-in-class clinical-stage Parkinson's disease treatment, weekly intravenous application of GM1-ganglioside in a blood-brain barrier crossing lipid nanoparticle, phase I/IIa study with significant reduction of MDS-UPDRS and no severe adverse events, a new mode of action with a strong data suggesting a disease-modifying effect on Parkinson's disease.
2. Talidox: best-in-class clinical-stage breast cancer treatment, monthly intravenous application of doxorubicin in a lipid nanoparticle, currently under review for market approval by Swissmedic, highest AUC and serum half-life of more than 120 hours, largely reduced undesired drug reactions and 70 percent disease control rate.

#### Intellectual Property

Strongest patent protection, latest patent: Liposomes comprising sphingomyelin US 11,607,385 B2 protecting the blood-brain barrier crossing capabilities of InnoMedica liposome technology.  
For more information visit our website:  
[www.innomedica.com](http://www.innomedica.com)

### Participants

**Presenter: Jonas Zeller** - CFO, InnoMedica Holding AG

## Gastrointestinal: EnteroTarget ApS

13:30 - 13:45

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

EnteroTarget ApS is a Copenhagen University spinout company that has developed and patented a 'First-in-Class' Inflammatory Bowel Disease (IBD) treatment. The company was established in 2018 after Professor Olsen and his research team made a remarkable discovery.

By re-purposing insulin and administrating this molecule locally within the bowel's, insulin receptors induce CA3 antioxidant proteins which in turn protects the epithelium cells from inflammation and allows the epithelial wall to begin restoration. As the epithelial wall is restored, inflammation is significantly reduced.

The unmet medical need for IBD is very large and growing 50% by 2030 to USD 30 Bn. This was evident by big Pharma acquiring clinical stage IBD treatments in 2023 with rich valuations. Currently, there is no cure for IBD and all existing and pipeline treatments targets the immune system, achieves a modest 30-40% improvement rate, while all patients experience a wide range of moderate to serious side-effects.

EnteroTarget's local treatment is a new and refreshing approach to IBD that has produced positive early-stage results and has demonstrated outperformance compared with existing/pipeline treatments which have used the same pre-clinical DSS models.

The re-purposing of Insulin comes with safety advantages also. The pharmacological properties are well-known compared with newly formed molecules and we have positive safety data available.

EnteroTarget is targeting three IBD indications with one indication being an orphan designated disease with two different patented products. EnteroCalm a rectal solution and EnteroShuttle a smart capsule.

### Participants

**Presenter: Jorgen Olsen** - CEO, EnteroTarget ApS

## Drug Discovery & Development: Alithea Genomics SA

13:45 - 14:00

Company Presentations: Coral 1

### Location: Coral 1

Alithea Genomics is a global leader in large-scale transcriptomics for drug discovery. Our revolutionary technology, DRUG-seq, enables transcriptomic profiling of drug response at an unprecedented scale, resolution, and data output.

The DRUG-seq workflow begins directly from cell lines and organoids, eliminating the need for time-consuming RNA extraction. We use RNA barcoding to label generated lysates, allowing massively multiplexed processing of tens to thousands of 96- and 384-well plates in just one week.

Our libraries can be sequenced on all major platforms, including Illumina, Element Bioscience, and Ultima Genomics. DRUG-seq is versatile, producing data for 3'-mRNA, full-length mRNA, or total RNA (including non-coding RNA species).

Validated across numerous cell lines and applications, DRUG-seq is used in tox screening and AI-driven drug discovery. It is available as both kits and services, provided directly and exclusively by Alithea.

Alithea Genomics has a direct presence in Europe and North America, with trusted partners in China, South Korea, Japan, and Australia. During this presentation, Alithea's CEO, Riccardo Dainese, will provide an in-depth look at our technology, highlight exciting large-scale projects, and offer insight into upcoming innovations.

### Participants

**Presenter: Riccardo Dainese** - CEO, Alithea Genomics SA

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Dermatology: Alphyn Biologics

13:45 - 14:00

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Alphyn is developing first-in-class therapeutics for severe and prevalent skin diseases using its unique multiple bioactive Zabalafin Multi-Target Therapeutic Drug Platform. Zabalafin Hydrogel, the company's lead candidate for atopic dermatitis (AD), is at the forefront of an evolution to treat the bacterial cause and exacerbation of the disease, in addition to directly treating the itch, inflammation, and infection that make AD so difficult to manage.

AD is a devastating chronic disease with significant impacts on quality of life. It is the most common form of eczema, with an estimated market size of \$118 billion globally. Current treatments fall short on efficacy and safety for worry-free long-term and continuous use and address only the immune component of the disease. Alphyn is well positioned to enter this large and growing market with a differentiated product that addresses these shortcomings.

Zabalafin Hydrogel completed two Phase 2a clinical trials, demonstrating efficacy against both the inflammatory and bacterial components of AD, with a strong safety profile for worry-free continuous and long-term use. Clinical trial results show superiority to current commercialized therapeutics and clinical-stage pipeline candidates.

Alphyn expects a faster, less expensive regulatory approval process than competitive products. Additionally, the company has a strong 4-part market protection program including (1) patent protection through 2042 and beyond, (2) 10 years FDA regulatory market exclusivity in the U.S. and EU and 8 years' regulatory exclusivity in the EU and Japan, (3) as well as protection from generics in the US, as there is currently no generic approval path from FDA-approved generics and (4) an estimated 15 year head start protection in drug raw material supply.

With the benefits of the Zabalafin Platform, Alphyn is also advancing its second drug candidate.

### Participants

**Presenter: Neal Koller** - CEO, Alphyn Biologics

## Crafting from lab to market: The business of science

14:00 - 14:45

Business of Biotech

### Location: Coral 2

The journey from concept to company is both exhilarating and challenging in the biotech industry, where innovation and investment intersect. This session will spotlight proven expertise in fostering groundbreaking biotech startups and Biovelocita, the first Pan-European investment strategy dedicated to accelerating biotech company creation. Industry leaders will discuss the critical ingredients for success, from identifying transformative science to scaling ventures across Europe. With insights into navigating early-stage challenges, securing funding, and driving innovation, this panel will provide a roadmap for translating bold ideas into thriving companies that redefine the future of healthcare.

### Participants

**Moderator: Gabriella Camboni** - Partner, Sofinnova Partners

**Panelist: Daniela Bellomo** - Director of Business Development Division, Ospedale San Raffaele

**Panelist: Celine Bouquet** - Business Development Neuroscience, Ophthalmology and Rare Diseases, Roche

**Panelist: Robin Carr** - CEO, MyricxBio

## Drug Discovery & Development: VariationalAI

14:00 - 14:15

Company Presentations: Coral 1

### Location: Coral 1

Founded in September 2019, we are a team of experienced AI/machine learning researchers and medicinal and computational chemists applying state-of-the-art generative AI to drug discovery. We work closely with biopharmaceutical partners to redefine the unit economics of drug discovery and development.

Variational AI has developed Enki, a small molecule drug discovery foundation model. Enki is a generative AI model that has been trained on many millions of high-quality experimental data samples and delivers novel and diverse potent (nM) and selective lead-like and synthesizable structures in weeks based on a preclinical TPP.

Trusted by leading pharma and biotechs, Enki is not software. It is available on a partnering/collab basis or as a platform. Variational AI has also generated early-stage assets available for out-licensing.

### Participants

**Presenter: Sree Vadlamudi** - EVP Business Development, VariationalAI

## Dermatology: Swiss Rockets AG

14:00 - 14:15

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Swiss Rockets is dedicated to developing groundbreaking medicines that will transform the treatment of cancer, infectious diseases, and autoimmune disorders.

We strive to be at the forefront of scientific discovery and clinical excellence, continuously pushing the boundaries of medical knowledge to address unmet medical needs. Through innovation and collaboration, we aim to build a thriving ecosystem that supports cutting-edge technologies and empowers inventors to turn their bold ideas into life-changing therapies.

Our ultimate goal is to improve global health outcomes and be a leader in the biotech industry.

### Participants

**Presenter: Andreas Emmenegger** - CFO and CBO, Swiss Rockets AG

## Drug Delivery: NanoSyrinx Ltd

14:15 - 14:30

Company Presentations: Coral 1

### Location: Coral 1

NanoSyrinx is a discovery stage synthetic biology company developing Nanosyringes as a next-generation platform technology for the targeted intracellular delivery of biological molecules.

Our vision at NanoSyrinx is to unlock the interior of the cell and the myriad therapeutic opportunities within that are currently difficult (or impossible) to drug, by enabling targeted, intracellular delivery of protein therapeutics.

NanoSyrinx closed a £10m financing round in August 2024, led by M Ventures (Amsterdam), BGF (London) and Octopus Ventures (London) and supported by Eli Lilly and Company, IQ Capital (Cambridge) and Jonathan Milner (Cambridge).

### Participants

**Presenter: James Lapworth** - CBO, NanoSyrinx Ltd

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring  
THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

**Rare and Orphan Diseases: Eleva GmbH**

14:15 - 14:30  
Company Presentations: Exhibit Hall Stage

**Location: Exhibit hall stage**

Eleva is a clinical-stage biopharma company that strives to bring novel therapies to patients in need. Partnerships are at the heart of our strategy and our unique moss-based platform and capabilities can unlock a range of 1st- and best-in-class biologics. We are currently advancing two proprietary clinical programs, which have the potential to change the life of patients affected from complement-related disorders and Fabry disease. Moreover, Eleva is looking to expand its pipeline with innovative compounds that will profit from its technology and expertise such as complex proteins, enzymes, cytokines and cytokine-fusion molecules, and various therapeutic antibody formats.

CPV-104 (recombinant human complement factor H; CFH) is a natural regulator of the C3 amplification loop. We demonstrated that CPV-104 can restore complement homeostasis without blocking the complement system's protective function. In contrast to other approaches, patients treated with CPV-104 are therefore not exposed to a higher risk of infection. We have validated the program's potential in indications with high unmet needs such as PNH, C3G, aHUS, dry AMD and ANCA vasculitis. A CTA to commence clinical studies in C3G was filed in Q4/2024 and the program has received ODD status. Our moss-based platform provides access to recombinant Factor H in previously unmet quantity and quality.

RPV-001 (recombinant and glylco-optimized human  $\alpha$ -Galactosidase; aGal) addresses the key disease-relevant pathway and deficiency in Fabry disease. Eleva's moss-based RPV-001 features favorable human-like glycosylation thereby driving cell uptake via the natural mannose receptor for significantly improved lysosomal deposition and organ distribution. As a result, RPV-001 has demonstrated safety and a more lasting reduction of Gb3 levels, a key clinical biomarker, up to 28 days post infusion in a clinical Phase 1b study. We are currently evaluating partnership structures to advance the program towards market approval.

**Participants**

**Presenter:** Henrik Luessen - CBO, Eleva GmbH

**Restoring the Picture: A new era in oncology**

14:30 - 15:15  
Therapeutic Insights

**Location: Coral 3**

Explore the advancing oncology landscape, with its multiple innovation areas and partnerships. Delve into the emerging therapies, latest breakthroughs in precision medicine and recent deals, along with addressing the shortcomings, enabling to redefine the future of cancer treatment.

**Participants**

**Moderator:** Linda Pullan - Business Development Consultant, founder, Pullan Consulting

**Panelist:** Khaterreh Ahmadi - Head of Search and Evaluation Team, European BD&L Hub, MSD

**Panelist:** Fabrizio Calisti - Medical Director, Angelini Ventures

**Panelist:** Anu Connor - VP, Head of Oncology External Innovation, IPSEN

**Panelist:** Catherine Pickering - CEO, iOnctura

**Drug Discovery & Development:**

14:30 - 14:45  
Company Presentations: Coral 1

**Location: Coral 1**

**CNS/Neurology: Ananda Scientific Inc**

14:30 - 14:45  
Company Presentations: Exhibit Hall Stage

**Location: Exhibit hall stage**

Ananda Scientific is a research driven biotech company developing life changing medicines to transform neuropsychiatric health. Our lead program is focused on PTSD - a chronic disease with high unmet need requiring lifelong treatment. Our two well powered phase-2 PTSD clinical trials (N=120 &140) are nearing completion at high quality academic sites. We are in early discussions with FDA to initiate a phase-3 PTSD trial by the end of 2025. Through a patented drug delivery technology developed at Hebrew University in Jerusalem, we have overcome the primary challenge with CBD delivery i.e. poor absorption and inconsistent uptake. This unique and proprietary delivery technology allows us to unmask the true potential of CBD which was demonstrated in an NIH funded Phase-1 PK study done head-to-head against Epidiolex®. The company is working on six phase-2 trials for multiple neuropsychiatric indications including PTSD, Opioid Use Disorder, Social Anxiety and Smoking Cessation. We have a strong patent estate covering global markets in 35+ countries and have built a GxP compliant drug development infrastructure with an experienced team capable to move multiple indications for FDA approval.

**Participants**

**Presenter:** Sohail Zaidi - CEO, Ananda Scientific Inc

**Drug Discovery & Development:**

14:45 - 15:00  
Company Presentations: Coral 1

**Location: Coral 1**

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring  
THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

**Dermatology: Verdant Scientific, Inc.**

14:45 - 15:00  
Company Presentations: Exhibit Hall Stage

**Location: Exhibit hall stage**

Verdant Scientific is a preclinical stage pharma startup developing a first-in-class, first-in-approach small molecule (VDT-002) for the treatment of atopic dermatitis (AD), more commonly known as eczema. AD is a chronic inflammatory skin condition which significantly impacts the lives of more than 220M people worldwide. There is no cure for the condition, and current treatments seek only to reduce the symptoms of the disease by modulating the body's immune response. Current treatment options are insufficient, with over 55% of AD patients reporting inadequate disease control. Verdant's approach to treating AD is completely different than current therapeutics - we are the first to target the primary driver of the signs and symptoms of the disease: the staphylococcus aureus bacteria which colonize AD patients' skin. It is widely known and has been extensively demonstrated in peer reviewed literature that s. aureus produces toxins that directly destroy the skin barrier and also induce pruritus, or itching. S. aureus bacteria only produce significant toxins when detect that they are in sufficient numbers. Our API stops the bacteria from being able to communicate, which effectively tricks them into thinking they are alone, and in turn stops the bacteria from producing the toxins that drive AD symptoms. Our elegant mechanism of action does not kill the bacteria, but rather stops them from causing harm, thereby not inducing selective pressure that could lead to resistance. This fact opens the door for VDT-002 being used in perpetuity in a prophylactic manner, preventing the signs and symptoms of the disease - in other words, a potential "cure" for many AD patients. Because of this and our likely safety profile, VDT-002 stands poised to usher in a paradigm shift in AD treatment, and to become a significant blockbuster drug in the process.

**Participants**

**Presenter: Robert Rushenberg** - CEO, Verdant Scientific, Inc.

**Trending: Startup spotlight pitch competition**

15:00 - 17:00  
Startup Spotlight

**Location: Coral 2**

The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe Spring audience. A panel of esteemed judges will evaluate the pitches and select the winners.

**Startup Finalists: \*Presenting in order**

**CereCura Nanotherapeutics:** CNS/Neurology

**Inverna Therapeutics:** Rare & Orphan Diseases

**MediSieve:** Cell & Gene Therapies

**BlackfinBio Ltd:** CNS/Neurology

**Dimer Pharmaceuticals:** Oncology

**Cycuria Therapeutics GmbH:** Oncology

**HHC Medical:** Cell & Gene Therapies

**STAb Therapeutics:** Cell & Gene Therapies

**Participants**

**Judge: Andre Albergaria** - Principal, Biovance Capital

**Judge: Jason Mellad** - Co-Founder, Start Codon

**Judge: Natalia Novac** - CEO & Chairwoman, Phialogics

**Judge: Giovanni Rizzo** - Partner Biotech Fund, Indaco Venture Partners

**Presenter: Louis-Philippe Bernier** - CEO, CereCura Nanotherapeutics

**Presenter: Poul Sorensen** - CEO, Inverna therapeutics

**Presenter: George Frodsham** - Founder & CEO, MediSieve

**Presenter: Peter Nolan** - CEO, BlackfinBio Ltd

**Presenter: Rakhee Ganti** - Founder and CEO, Dimer Pharmaceuticals

**Presenter: Nisit Khandelwal** - CEO, Cycuria Therapeutics GmbH

**Presenter: Niels Clausen** - CEO & Co-Founder, HHC Medical

**Presenter: Carolina Pola** - CEO, STAb Therapeutics

**Cardiovascular: AaviGen GmbH**

15:00 - 15:15  
Company Presentations: Coral 1

**Location: Coral 1**

AaviGen GmbH was founded in 2019 and is a pre-clinical stage biotechnology company. The company specializes in the development of transformative gene therapy medicinal products (GTMPs) for genetic and acquired cardiovascular and cardiopulmonary diseases. Utilizing a proprietary portfolio of genetically-engineered heart-specific Adeno-Associated Viruses (AAVs), AaviGen delivers therapeutic genes directly to the diseased heart cells via a single intravenous injection, with the aim of advancing safe and effective precision GTMPs for heart-related ailments. Integrating cutting-edge technologies with the interdisciplinary expertise of its founders - spanning clinical cardiology, virology and genetic vector engineering, GTMP development, health economics and regulatory affairs - AaviGen aims to address the unmet needs of millions of patients worldwide with its scalable vector platform and therapeutic pipeline, ultimately reshaping the clinical landscape of cardiovascular care.

**Participants**

**Presenter: Marc Lerchenmüller** - Managing Director and CFO, AaviGen

**Break and Breathe**

15:00 - 15:15  
Relax and Learn

**Location: Exhibit Hall Stage**

Break, breathe, and thrive!

Take a break from your busy schedule to recharge and rejuvenate by immersing yourself in moments of tranquility and self-care.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Sustainability Focus Area: Social Responsibility



# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Oncology: Persevere Therapeutics

15:15 - 15:30

Company Presentations: Coral 1

### Location: Coral 1

Persevere Therapeutics Inc is an oncology newco launched in February 2025 to acquire the rights to a clinical stage program (misetionamide - GP-2250) from Geistlich Pharma and their subsidiary, Panavance Therapeutics.

## Participants

**Presenter:** Greg Bosch - CEO, Persevere Therapeutics

## Sculpting Italy's biotech internationalization strategy: How to drive alliances

15:30 - 16:00

Ecosystem Innovation

### Location: Exhibit Hall Stage

An update on the progress of the working group for the internationalization of the biotech industry. The seminar will cover Italian programs and strategies to enhance the national Life Sciences and Biotech ecosystem globally, with a strong focus on attracting investments.

## Participants

**Moderator :** Matteo Picariello Signori - Head of the Global Startup Program, ICE Milano

**Panelist:** Anna Lambiase - Chairwomen, CDP Venture Capital SGR SpA

**Panelist:** Massimo Carnelos - Head of Technological Innovation and Startups, Italian Ministry of Foreign Affairs and International Cooperation

**Panelist:** Pierluigi Paracchi - CEO of Genenta Science, Moderator of the National Working Table for the Internationalization of the Biotechnology Sector, and Member of the Executive Committee of Assobiotec, Assobiotec

**Panelist:** Maria Cristina Porta - Director General, ENEA Tech and Biotech Foundation

**Panelist:** Luca Durante - Manager of Technology Promotion Office, Italian Trade Agency

## Biomarkers/Diagnostics/Imaging: Oncology: Sola Diagnostics GmbH

15:30 - 15:45

Company Presentations: Coral 1

### Location: Coral 1

Precision Prevention of Women's Cancers Through Epigenetic Innovation

#### Vision

At Sola Dx, our vision is to drive a global transformation in women's cancer prevention and early detection. We are committed to making innovative, accessible, and personalized solutions the standard of care-empowering women worldwide to live healthier lives.

#### Mission

Our mission is to bridge critical gaps in women's cancer prevention and diagnosis by delivering cutting-edge epigenetic solutions. Through personalized care and global accessibility, we strive to improve health outcomes for women everywhere.

#### Value Proposition

We create value by revolutionising primary and secondary cancer prevention with breakthrough innovations, including the WID®-easy test for the early detection of endometrial cancer and the WID®-can test for cervical cancer risk prediction. Our unwavering dedication to innovation ensures that we address today's most pressing diagnostic needs while paving the way for a future where personalised, accessible, and effective cancer prevention becomes the global standard of care.

#### Uniqueness

Sola Dx stands apart as a commercial-stage epigenetic diagnostics company, built on over 30 years of pioneering research in DNA methylation and gynecological cancers. Our technologies originate from the groundbreaking work of Prof. Martin Widschwendter and his internationally recognized academic team. Leveraging state-of-the-art epigenetic science, we develop diagnostic tests that are both highly accurate and minimally invasive. By focusing on precision prevention, we empower women with the knowledge and tools to make informed health decisions-establishing ourselves as leaders in women's health diagnostics.

## Participants

**Presenter:** Peter Kayatz - CEO, Sola Diagnostics GmbH

## Oncology: Cleara Biotech

15:45 - 16:00

Company Presentations: Coral 1

### Location: Coral 1

CLEARA is a private, Netherlands-based preclinical-stage biotherapeutics company, with an innovative discovery pipeline focused on targeting diseases with a high unmet medical need. The company's main Discovery engine is a platform technology of creation and iterative optimization of families of stabilized, D-amino acid, Cell-Penetrating Peptides (CPPs) designed for the specific purpose of disrupting protein-protein interactions. CLEARA's CPPs are optimized for in vivo safety, pharmacokinetics and stability, making them unique over competitive approaches. The targeted proteins are considered poorly 'druggable' by small molecule targeted agents that are currently available or under development.

## Participants

**Presenter:** Peter de Keizer - Managing Director, Cleara Biotech

## Tailor made: Ensuring digital health technologies are a perfect fit for regulatory decision making

16:00 - 16:45

Business of Biotech

### Location: Exhibit Hall Stage

This session focuses on how to communicate with pharmaceutical regulators about the use of digital health technologies in pivotal trials of drugs and biologics.

## Participants

**Moderator:** Steve Berman - Deputy VP, Science and Regulatory Affairs Strategy, Biotechnology Innovation Organization (BIO)

## Company Presentations

16:00 - 16:15

Company Presentations: Coral 1

### Location: Coral 1

# SESSIONS

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Runway to pharma's future: VCs on forecasting game-changing science

16:30 - 17:15

Therapeutic Insights

**Location:** Coral 3

As Pharma reshapes its pipelines to keep pace with market needs and scientific breakthroughs, venture capitalists play a pivotal role in identifying the next wave of transformative therapies. Drawing inspiration from Milan's legacy of trendsetting in fashion and art, this panel explores how VCs forecast what Pharma will need in five years' time. What defines game-changing science, and how can investors distinguish the breakthroughs that will set the future stage? Panelists will share their strategies for search and evaluation, reveal what truly stands out to Pharma, and discuss how aligning innovation with Pharma's evolving priorities can create a lasting impact. Join us for a forward-looking conversation on how to set the stage for a future that defines the industry.

### Participants

**Moderator: Mike Ward** - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate

**Panelist: Vanessa Carle** - Senior Associate, Forbion

**Panelist: Edward Hodgkin** - Managing Partner, Syncona

**Panelist: Fiona McLaughlin** - Senior Director, Johnson & Johnson

## Bubbly Reception

17:30 - 18:30

**Time:** 17:30 - 18:30

**Location:** EBD booth - #117

## Evening Networking Reception

19:00 - 23:00

**Time:** 19:00 – 23:00

**Location:**

Palazzo del Ghiaccio

Via Giovanni Battista Piranesi, 14, 20137 Milan, Italy

The Palazzo del Ghiaccio, an Art Nouveau gem from 1923, once housed one of the world's largest indoor ice rinks. Now, it's a vibrant venue for sports, fashion, and film. Enjoy a delightful Milan-inspired buffet with local drinks, and network in dedicated lounge areas, dance to a DJ on the dancefloor, or snap a photo to remember the night!

### Shuttle busses:

To reception - 18:30 – 19:15

Back to partner hotels - 21:00 – 23:00

# SCHEDULE

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	RELAX AND LEARN	LUNCH	THERAPEUTIC INSIGHTS	STARTUP SPOTLIGHT	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
06:00	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run	06:30 - Rise & Run
08:00	<p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p>08:45 - YesMilano Breakfast Panel</p> <p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>	<p>08:00 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45 - 10:45)</p> <p>08:30 - Partnering: one-to-one meetings (8:00 - 17:00 CET)</p>
09:00	09:30 - Market spotlight: How is innovation from China and Asia reshaping global biopharma?		<p>09:30 - Oncology: Immuneering Corporation</p> <p>09:45 - Oncology: AmMax Bio, Inc.</p>					
10:00	10:30 - The AI edit: What's the real deal?	10:00 - A work of art: Success as a first-time launcher in Europe	<p>10:00 - Oncology: Precirix</p> <p>10:15 - Oncology: Tempus AI</p> <p>10:30 - Oncology: FoRx Therapeutics AG</p> <p>10:45 - Immunology: Graph Therapeutics</p>					

# SCHEDULE

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	RELAX AND LEARN	LUNCH	THERAPEUTIC INSIGHTS	STARTUP SPOTLIGHT	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
11:00	11:30 - Sketching the future of biotech investment with Lilly Ventures	11:30 - Designing tomorrow's biotech: The interdependent ecosystem of therapeutic areas, research collaborators, and innovative funding models	11:00 - Immuno-Oncology: Immunos Therapeutics  11:15 - Immuno-Oncology: IO Biotech  11:30 - Immuno-Oncology: Oncolys BioPharma  11:45 - Immuno-Oncology: Altevax	11:00 - Break and Breathe				
12:00		12:00 - Brushing up on biotech financing: How important is venture debt?  12:30 - The perfect fit: Why Australia is a go-to destination for clinical trials	12:00 - Immunology: Ziphys NV  12:15 - Company presentations		12:00 - Lunch			

# SCHEDULE

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	RELAX AND LEARN	LUNCH	THERAPEUTIC INSIGHTS	STARTUP SPOTLIGHT	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
13:00	13:00 - Day in the life of an experienced dealmaker		13:00 - Drug Discovery & Development: Rejuvenate Biomed 13:15 - Drug Discovery & Development: Pioneering Medicines 13:30 - Drug Discovery & Development: InnoMedica Holding AG 13:45 - Drug Discovery & Development: Alithea Genomics SA					13:00 - Metabolic Diseases: MitoRx Therapeutics Limited 13:15 - Metabolic Diseases: Ciloa 13:30 - Gastrointestinal: EnteroTarget ApS 13:45 - Dermatology: Alphyn Biologics
14:00	14:00 - Crafting from lab to market: The business of science		14:00 - Drug Discovery & Development: VariationalAI 14:15 - Drug Delivery: NanoSyrinx Ltd 14:30 - Drug Discovery & Development: 14:45 - Drug Discovery & Development:			14:30 - Restoring the Picture: A new era in oncology		14:00 - Dermatology: Swiss Rockets AG 14:15 - Rare and Orphan Diseases: Eleva GmbH 14:30 - CNS/Neurology: Ananda Scientific Inc 14:45 - Dermatology: Verdant Scientific, Inc.

# SCHEDULE

DAY 2 - 18/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	BUSINESS OF BIOTECH	ECOSYSTEM INNOVATION	COMPANY PRESENTATIONS: CORAL 1	RELAX AND LEARN	LUNCH	THERAPEUTIC INSIGHTS	STARTUP SPOTLIGHT	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE
15:00		15:30 - Sculpting Italy's biotech internationalization strategy: How to drive alliances	15:00 - Cardiovascular: AaviGen GmbH 15:15 - Oncology: Persevere Therapeutics 15:30 - Biomarkers/Diagnostics/Imaging: Oncology: Sola Diagnostics GmbH 15:45 - Oncology: Cleara Biotech	15:00 - Break and Breathe			15:00 - Trending: Startup spotlight pitch competition	
16:00	16:00 - Tailor made: Ensuring digital health technologies are a perfect fit for regulatory decision making		16:00 - Company Presentations			16:30 - Runway to pharma's future: VCs on forecasting game-changing science		
17:00	17:30 - Bubbly Reception	17:30 - Bubbly Reception	17:30 - Bubbly Reception	17:30 - Bubbly Reception	17:30 - Bubbly Reception	17:30 - Bubbly Reception	17:30 - Bubbly Reception	17:30 - Bubbly Reception
19:00	19:00 - Evening Networking Reception	19:00 - Evening Networking Reception	19:00 - Evening Networking Reception	19:00 - Evening Networking Reception	19:00 - Evening Networking Reception	19:00 - Evening Networking Reception	19:00 - Evening Networking Reception	19:00 - Evening Networking Reception

# SESSIONS

DAY 3 - 19/03/2025

**Registration and badge pick-up opens (All day)  
/ Exhibition opens (All day) / Light breakfast  
(7:45- 10:45)**

07:45 - 08:15

Location: **Allianz MiCo**

Light Breakfast: **served until 10:45**

**Partnering: one-to-one meetings (8:00 - 17:00  
CET)**

08:15 - 08:45

One-to-one meetings at BIO-Europe Spring will be  
scheduled during the hours below:

Meetings on this day will start at **8:00 - 17:00 CET**.

**Next Generation: BioInnovation Institute,  
Modulate**

09:30 - 09:40

Company Presentations: Exhibit Hall Stage

**Location: Exhibit hall stage**

Skape Bio is a biotechnology company harnessing AI-powered protein design and synthetic biology to generate novel functional "Novobody" modulators of integral membrane proteins.

Our cutting-edge computational platform integrates deep evolutionary insights with advanced protein design methodologies tailored specifically for integral membrane proteins, generating molecules with exceptional developability and function. Our proprietary experimental platform enables high-throughput screening directly in human cells, bypassing the need for target solubilization and unlocking previously inaccessible GPCRs. This approach has demonstrated broad applicability across GPCR families, successfully delivering novel agonists and antagonists.

Through de novo design, Novobodies achieve precise control over target binding and possess biophysical properties that enable superior pharmacology, such as gut stability, potency, and selectivity, while offering a simpler manufacturing process compared to traditional antibodies. Skape Bio's in-cell screening platform evaluates tens of thousands of Novobody designs in their natural cellular context, accelerating target-directed discovery and optimization for first- and best-in-class indications in oncology, inflammation, metabolic disease, and neurology. Our robust platform infrastructure also supports future active learning for improved AI-driven Novobody design.

In addition to its in-house discovery programs, Skape Bio actively seeks partnerships with leading pharmaceutical companies to co-develop novel therapeutics and unique tool compounds.

Skape Bio is headquartered in Copenhagen, Denmark, a spinout from the three-year "Modulate" collaboration between the BioInnovation Institute and the University of Washington's Institute for Protein Design (IPD), founded and led by David Baker, recipient of the 2024 Nobel Prize in Chemistry.

**Participants**

**Presenter: Christoffer Norn** - Entrepreneur in Residence, BioInnovation Institute, Modulate

**Next Generation: InSilicoTrials**

09:40 - 09:50

Company Presentations: Exhibit Hall Stage

**Location: Exhibit hall stage**

InSilicoTrials is a leading technology company revolutionizing drug development through AI-powered simulation. Our platform provides pharmaceutical and biotech companies with access to a vast library of computational models, enabling them to simulate drug interactions, predict outcomes, and accelerate the discovery of new treatments. By leveraging digital patient twins and advanced AI algorithms, we offer a more efficient and cost-effective approach to drug development, reducing the need for early-stage human trials and improving decision-making throughout the process.

**Participants**

**Presenter: Mario Torchia** - COO, InSilicoTrials

**Next Generation: Menten AI, Inc.**

09:50 - 10:00

Company Presentations: Exhibit Hall Stage

**Location: Exhibit hall stage**

Menten AI is developing generative AI to design cyclic peptide therapeutics for challenging drug targets beyond the reach of small molecules and biologics. Its proprietary platform is capable of designing potent macrocycles with desirable drug properties including oral bioavailability and cell-permeability. The team has shown in vitro and in vivo validation of their platform for complex drug targets including challenging protein-protein interfaces (PPIs). The company has partnerships with top-10 pharma (e.g. Bristol Myers Squibb) to accelerate their preclinical drug discovery efforts. Menten AI is backed by top VCs including Social Impact Capital, Uncork Capital, Khosla Ventures, and Y-Combinator.

**Participants**

**Presenter: Hans Melo** - CEO, Menten AI, Inc.

# SESSIONS

DAY 3 - 19/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Next Generation: Amaro Therapeutics, Inc.

10:00 - 10:10

Company Presentations: Exhibit Hall Stage

### Location: Exhibit Hall Stage

Amaro is a therapeutic platform company focused on the emerging field of chemosensory receptors, specifically the TAS2R family, as therapeutic targets. The TAS2R family, more commonly known as bitter taste receptors, are G Protein-Coupled Receptors (GPCRs). These receptors are not confined to the oral cavity but ubiquitously expressed - every tissue expresses bitter taste receptors. In addition, TAS2R receptors are expressed on and in certain cells including cancer, immune and senescent cells. Despite being GPCRs, only recently has there been strong evidence of their potential as therapeutic targets. Our position is that bitterants are a necessary and fundamental nutrient to human health and that therapeutics, supplements, nutraceuticals, and functional foods designed to activate these receptors can provide significant benefit to patients and consumers across a spectrum of chronic diseases and conditions, e.g., obesity (activation of GLP-1 and CCK), diabetes, polycystic ovary syndrome (PCOS), inflammation, aging (clearance of senescent cells), etc. Further, it is likely that taste receptors - much like olfactory receptors - act in a concerted manner to tailor the body's immune and metabolic response to certain ligands (e.g., bitter compounds), in a systems-like manner. Amaro is at the forefront of this therapeutic sector and is establishing the preeminent discovery platform to exploit the bitter taste receptor system for the treatment of human diseases and conditions. The company is seeking Seed, possibly Series A, funding to advance the company's platform and preclinical program(s).

### Participants

**Presenter: Michael French** - CEO and Founder, Amaro Therapeutics, Inc.

## Next Generation: Biorevert Inc.

10:10 - 10:20

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Biorevert Inc. was found with proven records of scientific achievements in cancer and drug discovery platform to identify first-in-class targets and their relative mechanism of actions through computational simulation and analysis. We currently have several pipelines in colon, lung, and liver cancers for developing as small molecule (hit) and gene therapies (hit-to-lead) that can revert cancer cells into normal-functioning cells.

### Participants

**Presenter: Sea Choi** - Co-Founder/ Chief Global Strategist, Biorevert Inc.

## Next Generation: HD Immune GmbH

10:20 - 10:30

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

HD Immune GmbH (HDI), a privately owned company based in Vienna/Austria focused on the treatment of Huntington's disease using a passive antibody to remove mutant Huntingtin protein (HTT), which is the cause and driver of this fatal disorder. HDI has developed a human antibody that binds in the pM range to HTT, which is undergoing in vitro, in vivo and ex vivo pre-clinical characterization. The company was founded by Stefan Bartl (CEO,CSO) and Lionel Wightman (COO, CFO) in 2023.

### Participants

**Presenter: Stefan Bartl** - CEO & CSO, HD Immune GmbH

## Next Generation: OncoBone Therapeutics Ltd

10:30 - 10:40

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

OncoBone Therapeutics develops novel therapies for cancer patients with bone metastases utilising our novel innovative osteoimmuno-oncology (OIO)® concept. We identify potential OIO drug candidates from partners and confirm their preclinical efficacy for bone metastases in "early killer experiments" in our Bone Metastasis Technology Platform (BMTP)®. IND-enabling studies will be performed to effective assets that will be outlicensed to larger pharma/biotech companies for clinical development.

### Participants

**Presenter: Tiina Kahkonen** - CSO, OncoBone Therapeutics Ltd

## Next Generation: Mitodicure GmbH

10:40 - 10:50

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Mitodicure is the only biotech startup worldwide pursuing a curative approach for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), which is also the most serious sequel of Long COVID. ME/CFS is a disease with no effective treatment option. Driven by autoimmunity ME/CFS leads to severe muscular and mental fatigue, post-exertional malaise and other symptoms. Patients only have enough muscle energy to maintain bodily functions for simple survival. Disease severity scores are similar to MS. 25% of sufferers are in need of care, far more are unemployed. The prevalence of ME/CFS is 1.3% (according to the U.S. CDC) and is on the rise as post-acute infection syndrome due to COVID-19. This constitutes a large market of more than 6 million patients in the U.S., UK, France, Germany, Italy, Spain, and Japan alone with attractive peak sales estimates for our small molecule drug. ME/CFS is untapped by the biopharma industry because it was misclassified as a psychosomatic disorder, risky to target. However, recent investigations including electron microscopic findings show that mitochondrial damage and cell necrosis in skeletal muscle are the causes of fatigue and complaints. Mitodicure's oral tablet MDC002 heals these mitochondrial disturbances and, additionally, improves blood flow. With regard to preclinical proof-of-concept pharmacology, the German regulator BfArM considers our data to be sufficient to justify clinical trials in ME/CFS. Mitodicure is a young company, has completed its pre-seed financing in 2024, and is led by a very experienced biopharma team with translational expertise. We aim to have completed all IND-enabling studies in 18 months. In contrast to symptom-oriented off-label therapies, our innovative approach can favorably influence the course of ME/CFS for the first time. MDC002 also has potential in the indications Fibromyalgia, Lyme disease and Gulf War syndrome as well as in chronic fatigue associated with Ehlers-Danlos and Marfan syndromes.

### Participants

**Presenter: Harald Pacl** - CEO, Mitodicure GmbH



# SESSIONS

DAY 3 - 19/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Next Generation: Symbiotica Therapeutics

10:50 - 11:00

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Symbiotica Therapeutics is a newborn biotech innovative start-up based in Italy. We developed a revolutionary delivery system that goes beyond genetic therapy or lipid nanoparticles systems, which are used in modern therapies. Our proprietary delivery system called symbiotic therapy, uses symbiotic particles injected under the host skin as a "tattoo" to continuously deliver over time a functionalized peptidic and/or proteic therapeutic agent to mediate: i) an hormonal signaling, ii) an intra-cellular or intra-nuclear function or iii) specific organ or cell populations delivery. Our delivery system showed impressive results during in vitro and in vivo experiments, allowing us to deposit a patent recently. As next step, we plan to run a pre-clinical trial in mice and non human primates in the next few years before to reach the clinical stage.

### Participants

**Presenter: Gabriele Morabito** - Drug Delivery, Symbiotica Therapeutics

## Next Generation: KalphaTech

11:00 - 11:10

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

KalpaTech, a Croatian deep-tech startup, is revolutionizing materials analysis by offering unprecedented speed, reliability, and predictive power. Our state-of-the-art structural analysis of small-drug molecules is built on decades of expertise in structural chemistry and solid-state characterization. Founded in 2023 by an interdisciplinary team of five PhDs, we leverage our experience in crystallography, data science, and machine learning to build our AI engine.

Partnered with leading Croatian research institutions, KalpaTech offers innovative services to early-drug discovery companies, CROs, and CDMOs, optimizing solid form analysis, polymorph, solubility, and stability screening. Our technology requires only milligrams of material to identify and structurally characterize various forms, including solvates and polymorphs, without the need for hardware upgrades.

KalpaTech accelerates drug development timelines and reduces risks and costs for our partners and clients by providing fast, accurate, and comprehensive materials analysis. Let us help you innovate.

### Participants

**Presenter: Stipe Lukin** - CEO, KalpaTech

## Next Generation: ProtOS

11:10 - 11:20

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

ProtOS is an AI-first protein design company developing therapeutics to treat undruggables. We generate AI proteins that allow us to go beyond the limits of small molecule drugs, harnessing nature's protein ingenuity - yet engineering it to perform novel functions. Our AI foundation models create therapeutic proteins that are safe and effective by design, creating a paradigm shift in drug development - from accidental discovery to intentional design.

### Participants

**Presenter: Ofer Springer** - CTO and President, ProtOS

## Next Generation: lowalBO, Inc

11:20 - 11:30

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

After isolating a molecule that is found in the urine of men who practice Transcendental Meditation, a modification was made in its structure to have it resemble Enterolactone, a known anti-cancer natural product. This modified molecule was tested in-vitro giving the following results: BREAST CANCER: 98% KILLED IN 24 HRS PROSTATE CANCER: 75% KILLED IN 72 HRS The molecule (and various additional substituents) has been patented. Toxicological study using engineered foreskins (to make them behave as stem cells) was done and it appears as though the molecule acts similar to Hydroxyurea. (a known anti-cancer drug.)

### Participants

**Presenter: Tom McCorkle** - CEO, lowalBO, Inc

## Next Generation: Forge Genetics

11:30 - 11:40

Company Presentations: Exhibit Hall Stage

### Location: Exhibit hall stage

Forge Genetics is a University of Nottingham spin-out contract research organization specializing in strain development services.

### Participants

**Presenter: Craig Woods** - CEO, Forge Genetics

### Lunch

12:00 - 14:00

Lunch

## Break and Breathe

14:30 - 14:45

Relax and Learn

### Location: Exhibit Hall Stage

Break, breathe, and thrive!

Take a break from your busy schedule to recharge and rejuvenate by immersing yourself in moments of tranquility and self-care.

These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.

Open to all, without prerequisites.

Sustainability Focus Area: Social Responsibility

## MIND - Milano Innovation District

14:30 - 16:30

Milano Tour 1

Visit to the District's scientific anchors. Research *Hospital Galeazzi-Sant'Ambrogio*, internationally renowned for its top-ranked Orthopedics department (with presentations by Research *Hospital San Raffaele* and the national TT network *PerfeTTO*), followed by *Human Technopole*, Italy's state-of-the-art research center for Genomics, Neurogenomics, and Computational Biology.

This is a unique opportunity to engage with **leading research institutions and companies**, fostering strategic collaborations.

Advance sign-up is required to participate. [Register now to secure your spot!](#)

## OpenZone - OpenZone Scientific Campus

14:30 - 16:00

Milano Tour 2

Meeting and networking with some of its leading companies: *Zambon*, *AGC Biologics*, *Axxam*, *Champions Oncology* and *Sibylla*.

This is a unique opportunity to engage with **leading research institutions and companies**, fostering strategic collaborations.

Advance sign-up is required to participate. [Register now to secure your spot!](#)

# SESSIONS

DAY 3 - 19/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT

March 17–19, 2025 | Milan, Italy

March 25–26, 2025 | Digital Partnering

## Ciao Milano, Olá Lisboa

15:30 - 16:30

Ciao Milano, Olá Lisboa

**Time:** 15:30 – 16:30

**Location:** BIO-Europe Spring Exhibition Hall, Allianz  
MiCo

<https://bio-europespring2025.expofp.com/?ciao-milano-ola-lisboa>

# SCHEDULE

DAY 3 - 19/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	LUNCH	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE	RELAX AND LEARN	MILANO TOUR 1	MILANO TOUR 2	CIAO MILANO, OLÁ LISBOA
07:00	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)	07:45 - Registration and badge pick-up opens (All day) / Exhibition opens (All day) / Light breakfast (7:45- 10:45)
08:00	08:15 - Partnering: one-to-one meetings (8:00 - 17:00 CET)	08:15 - Partnering: one-to-one meetings (8:00 - 17:00 CET)	08:15 - Partnering: one-to-one meetings (8:00 - 17:00 CET)	08:15 - Partnering: one-to-one meetings (8:00 - 17:00 CET)	08:15 - Partnering: one-to-one meetings (8:00 - 17:00 CET)	08:15 - Partnering: one-to-one meetings (8:00 - 17:00 CET)
09:00		09:30 - Next Generation: BioInnovation Institute, Modulate 09:40 - Next Generation: InSili-coTrials 09:50 - Next Generation: Menten AI, Inc.				
10:00		10:00 - Next Generation: Amaro Therapeutics, Inc. 10:10 - Next Generation: Biorevert Inc. 10:20 - Next Generation: HD Immune GmbH 10:30 - Next Generation: OncoBone Therapeutics Ltd 10:40 - Next Generation: Mitodicure GmbH 10:50 - Next Generation: Symbiotica Therapeutics				

# SCHEDULE

DAY 3 - 19/03/2025

BIO-Europe Spring

THE SPRINGTIME PARTNERING EVENT  
March 17–19, 2025 | Milan, Italy  
March 25–26, 2025 | Digital Partnering

TIME	LUNCH	COMPANY PRESENTATIONS: EXHIBIT HALL STAGE	RELAX AND LEARN	MILANO TOUR 1	MILANO TOUR 2	CIAO MILANO, OLÁ LISBOA
11:00		11:00 - Next Generation: KalphaTech  11:10 - Next Generation: Pro-tOS  11:20 - Next Generation: lowal-BO, Inc  11:30 - Next Generation: Forge Genetics				
12:00	12:00 - Lunch					
14:00			14:30 - Break and Breathe	14:30 - MIND - Milano Innovation District	14:30 - OpenZone - OpenZone Scientific Campus	
15:00						15:30 - Ciao Milano, Olá Lisboa